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Abstract 
 
        Obesity is the top risk factor for the development of type 2 diabetes mellitus 
in humans. Obese adipose tissue, particularly visceral depots, exhibits an 
increase in macrophage accumulation and is described as being in a state of 
chronic low-grade inflammation. It is characterized by the increased expression 
and secretion of inflammatory cytokines produced by both macrophages and 
adipocytes, and is associated with the development of insulin resistance. Based 
on these observations, we investigated the potential role of macrophage 
infiltration on whole body metabolism, using genetic and diet-induced mouse 
models of obesity.  
         Using flow cytometry and immunofluorescence imaging we found that a 
significant percentage of macrophages proliferate locally in adipose tissue of 
obese mice. Importantly, we identified monocyte chemoattractant protein 1 
(MCP-1) as the stimulating factor. We also found that ATMs can be targeted for 
specific gene silencing using glucan encapsulated siRNA particles (GeRPs). 
Knockdown of the cytokine osteopontin improved regulation of systemic glucose 
levels as well as insulin signaling in adipocytes. Conversely, targeting lipoprotein 
lipase (LPL) abrogated the buffering of lipid spillover from adipose tissue, 
resulting in increased hepatic glucose output. Finally, silencing of the master 
regulator of inflammation NF-κB in resident liver macrophages called Kupffer 
cells significantly improved hepatic insulin signaling. Thus this work 
demonstrates that macrophages can regulate whole body metabolism.  
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PART 1: Insulin resistance and glucose metabolism 
        Insulin is an important hormone involved in regulating the utilization and 
storage or energy rich molecules such as glucose, glycogen and lipids. Part 1 will 
introduce major target organs for insulin, namely the liver and adipose tissue. It 
will also describe what happens when insulin signaling fails, particularly in the 
obese state, leading to type 2 diabetes mellitus (T2DM). 
Insulin signaling pathway 
        Insulin is a peptide hormone that is produced and secreted by the pancreas, 
specifically in the Islets of Langerhans, which contain specialized insulin-
producing beta cells (1). Owing to its importance in regulating whole body energy 
balance, particularly concerning carbohydrate and lipid metabolism, insulin 
expression, secretion and action have been extensively studied for almost a 
century. Although glucose is the primary stimulator of insulin secretion, other 
circulating nutrients such as amino acids and fatty acids can also act as insulin 
secretagogues (2). Translation of insulin does not result in the mature insulin 
protein, but instead a preproinsulin is synthesized on the rough endoplasmic 
reticulum (RER). Removal of the amino terminal sequence yields proinsulin, 
which is directed into the regulated secretory pathway and is further cleaved by 
endoproteases to produce insulin and C-peptide. The mature protein and C-
peptide are finally stored in crystalline granules until secretion (3). Subsequent 
secretion of insulin in response to glucose is biphasic, owing to the existence of 
two distinct insulin granule pools. The readily releasable pool (RRP) is docked at 
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the cell surface, where calcium channels allow for rapid fusion with the plasma 
membrane and is therefore responsible for the initial or first phase of secretion 
(4). The second reserve pool is actively recruited to plasma membrane and 
results in a prolonged secretion of insulin called the second phase (5). Once 
insulin is secreted, it circulates to its target tissues where it binds and signals 
through its receptor. 
        The insulin receptor (IR) is a member of the receptor tyrosine kinase family 
of receptors and is expressed as two isoforms: IR-A and IR-B (6). IR-A is 
predominantly expressed during neonatal development, and has an affinity for 
another signaling molecule called insulin-like growth factor II (IGF-II) which is 
important for growth and development, and tends to be up-regulated in cancer 
cells (7). The IR-B isoform is more highly expressed in adult tissues such as 
adipose, muscle and liver, where it is involved in metabolic regulation (6). Insulin 
binding causes dimerization and autophosphorylation of the IR, thus activating 
the receptor. A number of IR substrates have been reported in the literature, 
however the most studied and metabolically relevant of those is the insulin 
receptor substrate (IRS) family, which number from IRS-1 to IRS-6 (8). They are 
phosphorylated on several tyrosine residues, and thus act as protein scaffolds for 
further downstream signaling complexes by binding proteins containing Src-
homology 2 (SH2) domains (9). One such protein is phosphoinositide 3-kinase 
(PI3K). Binding of its regulatory subunit to IRS results in activation of its catalytic 
subunit, which phosphorylates phosphatidylinositol 4,5 bisphosphate (PIP2) to 
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produce phosphatidylinositol (3,4,5) triphosphate (PIP3), a lipid second 
messenger (8).  
        The proteins that mediate most of the physiological effects of PIP3 belong to 
a subset of the AGC (PKA, PKG, PKC) family of kinases, which have a similar 
structure and are activated by phosphorylation of two serine and threonine 
residues (10). PIP3 is anchored to the plasma membrane where it recruits and 
binds the pleckstrin homology (PH) domain of 3-phosphoinositide-dependent 
protein kinase 1 (PDK-1), which in turn phosphorylates and activates AGC 
kinases such as p70 ribosomal S6 kinase (S6K), serum- and glucocorticoid-
induced protein kinase (SGK) and Akt/protein kinase B (PKB) (8). The family 
consists of three different isoforms Akt1, Akt2 and Akt3 encoded by different 
genes (11), with Akt2 being the most abundantly expressed and critical isoform in 
insulin-sensitive tissues (12). The Akt family of serine/threonine kinases 
represents a critical signaling node in the insulin pathway by regulating the 
activity and expression of a wide range of proteins such as transcription factors, 
enzymes and regulators of apoptosis, survival and the cell cycle (13). It is also 
important for mediating insulin’s action in energy homeostasis, as will be 
discussed in subsequent sections.  
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Figure 1.1- The Insulin signaling pathway 
 
Figure 1.1 - The insulin signaling pathway 
Insulin binding to its receptor results in dimerization and activation of the receptor 
via autophosphorylation. The activated receptor in turn phosphorylates one of its 
major targets, Insulin Receptor Substrate (IRS). IRS is bound by PI3 Kinase, 
which converts PIP2 to PIP3 at the plasma membrane. Finally PIP3 activates a 
class of kinases that includes Akt, which is a major signaling node and regulator 
of energy homeostasis.  
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Liver metabolism 
Physiology and function of the liver         
        The liver is the largest organ in the human body and accounts for 2 to 3% of 
average body weight. It is highly vascularized and receives up to 25% of cardiac 
output at rest, which is more than any other organ. It is often described as having 
two lobes, which are characterized based on morphology and function (14). The 
liver is composed of five main cell types: hepatocytes, which constitute 80% of 
the cell population (15), endothelial cells, stem cells, biliary cells, stellate cells 
and immune cells (16). The liver’s extensive access to the circulation is a feature 
that makes it uniquely adapted to its major functions. These include synthesis of 
plasma proteins and clotting factors such as albumin and fibrinogen respectively 
(17), systemic immune surveillance facilitated by robust innate and adaptive 
immune responses (16), detoxification of harmful molecules by xenobiotic 
biotransformation enzymes (18), and regulation of systemic glucose 
concentration as discussed below. 
        Maintaining blood glucose levels in the range of 4-6 mM is critical for 
sustained normal body function and homeostasis(19). The pancreas, which 
contains insulin-secreting β-cells and glucagon-secreting α-cells, serves an 
important role in modulating these levels (20). Secretion of the glucagon 
hormone is stimulated by a drop in the blood glucose levels, signaling the 
conversion of hepatic glycogen stores into glucose. This is also accompanied by 
increased gluconeogenesis, which altogether returns circulating levels to normal. 
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Conversely, a rise in blood glucose levels, typically postprandial, stimulates 
insulin secretion, which counteracts the action of glucagon in the liver by curbing 
glucose production (20, 21). In this way, the pancreas acts as a glucose-sensing 
organ, regulating liver glucose output as necessary.  
Glucose and lipid metabolism         
        Glucose production is achieved via two different pathways, glycogenolysis 
and gluconeogenesis. Glycogenolysis involves the catalytic conversion of stored 
hepatic glycogen into glucose (22). Once glycogen is depleted, gluconeogenesis 
is stimulated and involves a series of enzymatic reactions that convert pyruvate 
into glucose. Pyruvate is generated in the cytosol from other metabolites such as 
amino acids and lactate and then converted to oxaloacetate by pyruvate 
carboxylase. Oxaloacetate is converted into phosphoenolpyruvate (PEP) by the 
gluconeogenic enzyme phosphoenolpyruvate carboxykinase (PEPCK). PEP is 
then sequentially converted into glucose-6-phosphate, which is the final 
precursor to glucose. It is converted into glucose by another key enzyme 
glucose-6-phosphatase (Glu-6-Pase) (22, 23).  
        Glucagon signaling increases the expression and enzymatic activity (by 
phosphorylation) of gluconeogenic enzymes by raising cAMP levels. This is a 
result of the activation of adenylate cyclase (AC), which is coupled to the 
glucagon receptor. cAMP-dependent kinase activity is thus increased, driving 
phosphorylation of gluconeogenic enzymes(22). Particularly, PEPCK gene 
transcription is rapidly induced by cAMP analogues (24) and there is evidence 
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that cAMP also blocks PEPCK mRNA transcript degradation(25). Conversely, 
insulin signaling stimulates glycolytic enzyme activation, shifts substrate 
concentrations in favor of glycogenesis and counteracts the transcription-
inducing effects of cAMP (19, 21, 22, 24).  
        The liver is also an important organ for the handling and synthesis of 
triglycerides or triacylglycerol (TAG). These are neutral lipids that are composed 
of a glycerol backbone and three acyl chains, which are generated through the 
process of lipogenesis and released into the circulation (26). This process 
requires the esterification of fatty acids to the substrate glycerol-3-phosphate 
(G3P). G3P is generated first by phosphorylation of fructose-6-phosphate (F6P) 
by phosphofructo kinase (PFK) to fructose-1,6-bisphosphate (F16BP), which is 
subsequently hydrolyzed to produce G3P. For fatty acid production, pyruvate is 
first converted to citrate in the mitochondria and transported back into the cytosol 
where ATP-citrate Lyase (ACLY) subsequently converts it to acetyl CoA. Fatty 
acids are derived through a series of conversions by key lipogenic enzymes 
namely acetyl CoA carboxylase (ACC), fatty acid synthase (FAS), Fatty acyl-CoA 
elongases (Elovls) and finally stearoyl-CoA desaturases (SCDs)(23). This 
conversion of carbohydrates into fatty acids is also called de novo lipogenesis 
and is mostly carried out in the liver, though it occurs in adipose tissue as well 
(27). Free fatty acids (FFAs) can also be taken up from the circulation by the 
hydrolytic action of lipoprotein lipase (LPL) on circulating lipid-rich chylomicron 
particles (26). Insulin promotes lipogenesis by signaling through Akt to activate 
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transcription factors that up-regulate the expression of important enzymes as 
listed above (23). However, insulin-independent activation of lipogenesis is also 
observed and is thought to be driven by dietary carbohydrates (28). 
 
Glucose and lipid metabolism in adipose tissue 
Anatomy and Physiology of Adipose Tissue 
        Adipose tissue (AT) is a lipid storage organ that primarily acts as an energy 
reservoir and endocrine organ. AT is divided into two major depots: 
subcutaneous AT (SAT) is located under the skin and acts as cushion from 
mechanical stress, insulation from heat loss and a barrier against dermal 
infection, and visceral AT (VAT) is proximal to organs of the viscera or ‘trunk’ (29, 
30). The parenchymal cell of the adipose tissue is the adipocyte, which adopts a 
different morphology and subcellular configuration depending on the primary 
function of the depot in which it is located. Other cell types that constitute AT 
include endothelial cells, immune cells, fibroblasts and adipocyte precursors. The 
cellular makeup as well as the morphology of AT can vary greatly with a number 
of genetic, metabolic, and environmental factors (30-35). Although originally 
thought of as just a fat storing organ, AT secretes a host of signaling molecules 
including hormones and cytokines, eliciting both local and systemic effects, thus 
establishing it as an important endocrine organ as well (35). This aspect of AT 
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function and its implications on whole body metabolism will be discussed in 
further detail in later sections. 
        There are three classifications of adipocytes to date: white adipocytes, 
brown adipocytes and the more recently characterized pink adipocytes (33). The 
white adipocyte is characterized by a single large lipid droplet (unilocular), which 
takes up 90% of the cell’s volume thus confining the nucleus to a small area 
against the plasma membrane. The whitish/clear appearance of the lipid droplet 
under microscopy gives these cells their name. Brown adipocytes on the other 
hand are polygonal in morphology, have several lipid droplets in their cytoplasm 
(multilocular) and a more centralized roundish nucleus (29). Despite the name, 
pink adipocytes are not intermediates between the white and brown state, but 
rather they are subcutaneous white adipocytes that transdifferentiate into lipid 
laden epithelial cells during pregnancy to form the milk-secreting mammary gland 
in females (33). Since white and brown adipocytes are the most studied and 
metabolically active types, they will be discussed in further detail.  
White Adipose Tissue 
        During times of positive energy balance, white adipose tissue (WAT) stores 
energy in the form of TAG, which can be hydrolyzed into fatty acids via lipolysis 
during times of energy demand. In this way WAT acts to maintain energy 
homeostasis (30). TAG is produced via lipogenesis, utilizing a similar pathway as 
described earlier (36). In adipocytes, insulin stimulates the uptake of glucose 
from the circulation by signaling the translocation of the primary adipocyte 
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glucose transporter GLUT4 from intracellular vesicles to the plasma membrane 
(37). In vitro data generated from 3T3-L1 adipocytes shows this to be dependent 
on Akt activation (38). Subsequently, glucose is converted into G3P for FFA 
esterification as seen in the liver. Fatty acids are mainly derived from the 
hydrolysis of circulating lipoproteins by LPL and uptake of resultant FFAs (27). 
These are subsequently re-esterified to the intracellular G3P pool. Aside from 
promoting glucose uptake, insulin also acts to promote lipogenesis in adipocytes 
by enhancing FFA uptake by increasing the gene expression and activity of LPL 
(39, 40), stimulating de novo lipogenesis, although to smaller scale than in the 
liver (27), and promoting the translocation of two proteins involved in FFA 
diffusion and capture, i.e., fatty acid transporter (CD36) and fatty acid transporter 
protein 1 (FATP1), to the plasma membrane (41). Furthermore, insulin-stimulated 
FATP1 translocation is blunted by PI3K and MAPK pathway blockade, 
suggesting a mechanism for this process (42). In addition, insulin has antilipolytic 
effects, which promote the storage of TAG.   
        Lipolysis is the opposite of esterification and involves the stepwise 
enzymatic breakdown of TAG back into glycerol and FFA during periods of 
negative energy balance (43). Lipolysis is driven by catecholamine and 
natriuretic peptide (NP) stimulation of β-adrenergic receptors (β-AR) (44) and 
natriuretic peptide receptor (NPR) (45), respectively. In the case of β-ARs, which 
are G-protein-coupled-receptors, catecholamine stimulation results in interaction 
of the stimulatory Gs subunit with AC, thus activating it to convert ATP to the 
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second messenger cAMP. This increase in intracellular cAMP activates protein 
kinase A (PKA) which phosphorylates a lipid droplet-associated protein perilipin 1 
(PLIN1) (46) and hormone sensitive lipase (HSL) (47), so-called due to its tight 
regulation by catecholamines and insulin (48). PLIN1 phosphorylation promotes 
the release of a co-activator for adipose triglyceride lipase (ATGL) called 
comparative gene identification-58 (CGI-58), therefore activating ATGL, which is 
the rate-limiting step of lipolysis (49). ATGL hydrolyzes TAG to diacylglycerol 
(DAG), which releases one FFA and HSL hydrolyzes DAG to produce 
monoacylglycerol (MAG) and another FFA. The final step is MAG hydrolysis by 
monoglyceride lipase (MGL), yielding glycerol and a third FFA (43). NPR 
stimulation also results in PLIN1 and HSL phosphorylation; however, the kinase 
involved is cGMP-dependent kinase (PKG). PKG is activated by cGMP, the 
levels of which are increased by the guanylyl cyclase (GC)-mediated conversion 
of GTP to cGMP in response to NPR stimulation (45). Insulin exerts an 
antilipolytic effect that stems from IRS1/2 phosphorylation and subsequent 
PI3K/Akt activation of phosphodiestrase III B (PDE3B), which degrades cAMP to 
5’-AMP. A drop in intracellular cAMP reduces PKA activity, resulting in decreased 
PLIN1 and HSL phosphorylation (50). The FFAs mobilized via lipolysis are 
released into the circulation, where they can be taken up and utilized as an 
energy source by other tissues such as the liver, muscle and brown adipose 
tissue.  
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Brown Adipose Tissue 
        Brown adipocytes are located in the brown adipose tissue (BAT), which has 
high mitochondrial content and is highly vascularized (33). Previously thought to 
only exist in in the interscapular region of rodents and human infants, recent 
evidence shows that adult humans also possess BAT primarily in the 
supraclavicular and neck region (51). Although brown adipocytes also contain 
lipid droplets, their main function is to utilize lipid and glucose as fuel for heat 
generation via non-shivering thermogenesis (31, 52). BAT is uniquely adapted for 
this role due to the presence of a high number of mitochondria and high 
expression of uncoupling protein 1 (UCP-1). UCP-1 generates heat by 
uncoupling oxidative phosphorylation from the production of ATP via ATP 
synthase. It provides an alternative route for release of the proton motive force 
built up by the electron transport chain across the mitochondrial inner membrane. 
This in turn increases substrate oxidation and the dissipation of resulting energy 
as heat (53). BAT thermogenic activity is controlled by beta-3 Adrenergic 
Receptor (β3-AR) signaling, and while a significant increase in activation is 
observed with cold exposure and re-feeding, it can also occur during starvation. 
Additionally, insulin appears to play a similar role in BAT as in WAT; promoting 
glucose uptake and the storage of lipid as TAG (52).  
        So whereas these tissues do share similarities, they are adapted to perform 
almost opposite functions: WAT stores energy while BAT burns energy. It is 
therefore also important to note that there is a growing interest in understanding 
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the recently observed phenomenon of “browning”. This involves the acquisition of 
brown adipocyte characteristics by white adipocytes under a number of stimuli 
including cold, exercise, catecholamines and PPARγ agonists (54). These beige 
or brite cells have more mitochondria, lipid droplets, and UCP1 expression than 
white adipocytes, and the mechanisms driving this adaptation are currently under 
vigorous investigation (54). The importance of understanding this phenomenon 
and its overall contribution to systemic insulin sensitivity and glucose disposal will 
be discussed in the next section.  
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Figure 1.2 - Lipogenesis and lipolysis pathways in the adipocyte.  
 
	  	  
 
Figure 1.0-2 - Lipogenesis and lipolysis pathways in the adipocyte 
1) Glucose taken up via GLUT4 is converted to glucose-6-phosphate (G6P) by 
hexokinase 2) G6P is converted to pyruvate by pyruvate kinase 3) Pyruvate is 
transported into the mitochondria where it is converted first to Acetyl CoA and 
then citrate, which is transported back to the cytosol 4) Citrate is reverted to 
Acetyl CoA by ATP-citrate lyase 5) Acetyl CoA is subsequently converted to 
Malonyl CoA by Acetyl CoA carboxylase 6) Fatty acid synthase converts Malonyl 
CoA to palmitate 7) Palmitate and other FFAs taken up from the extra cellular 
space and chylomicron hydrolysis are esterified to glycerol-3-phosphate (G3P). 
G3P is derived from glucose via glycolysis and phosphorylation of fructose-6-
phosphate. G3P is also produced in the final step of lipolysis. 8) Lipolysis is 
initiated by activation of adipose triglyceride lipase, which hydrolyzes TAG to 
DAG 9) DAG is subsequently hydrolyzed to MAG by hormone stimulated lipase        
10) Finally MAG is hydrolyzed to FFA and G3P. One FFA is released at each 
step of hydrolysis.  
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Obesity and Type 2 Diabetes Mellitus 
Obesity and adipose tissue expansion 
        Adipose tissue is a very plastic organ that has the ability to expand and 
adapt in situations of excess/surplus energy (55). This is often the result of a high 
caloric diet and a sedentary lifestyle, which results in high energy intake, low 
energy expenditure and weight gain attributed to increased fat mass (56). If 
unchecked, this energy imbalance results in the development of obesity. An 
individual is characterized to be obese if their body mass index (BMI) is above 30 
kg/m2. BMI is calculated by dividing the mass (in kilograms) of an individual by 
the square of their height (in meters). A BMI under 19 kg/m2 is considered 
underweight, whereas19-24.9 kg/m2 is the normal range, and 25-29.9 kg/m2 is 
overweight (57).  
        The incidence of obesity in western societies, particularly here in the U.S, 
has been rising over the past four decades as a result of an increase in per 
capita energy intake (58). Indeed, recent data shows about one third of the U.S 
population is obese, with another third falling in the overweight category (59). 
This is problematic because obesity and its associated sequelae are currently the 
leading cause of morbidity, mortality and reduced quality of life. These sequelae 
are collectively referred to as the metabolic syndrome and include increased 
blood sugar, high blood pressure and abnormal triglyceride/cholesterol, which 
together raise the risk of diabetes, stroke and cardiovascular disease (60). And 
although diet and lifestyle play a central role in the development of obesity, 
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genetic factors must also be taken into account because 45-75% of BMI 
variability can be explained by heritable factors (61).  
        Adipose tissue expansion is observed in both SAT and VAT depots and is 
considered to be an adaptive response to a positive energy balance. However, in 
the extreme case of obesity it can become pathological as described above. 
Research into the underlying causes of metabolic syndrome has given rise to the 
hypothesis that although SAT and VAT both undergo this expansion, VAT 
expansion is maladaptive compared to SAT expansion (62). This so-called 
visceral obesity is associated with impaired glycemic and lipid control and the 
development of cardiovascular complications (63). Indeed, studies have also 
shown that men tend to gain more visceral than subcutaneous fat, which is 
associated with a higher cardiovascular risk. Conversely premenopausal women 
preferentially store subcutaneous fat, but switch to visceral deposition after 
menopause and thus increase their risk of cardiovascular events in a manner 
reminiscent to that of men (64).  
        The depot-dependent risk for driving the metabolic syndrome stems from 
the ability of each depot to adequately adapt to the storage of excess lipid. 
During expansion, AT adapts by increasing adipocyte size and adipocyte 
number, or hypertrophy and hyperplasia, respectively (65). SAT has more 
expandability than VAT, which is suggested to be the source of its protective 
effects (55). VAT primarily expands by hypertrophy, and adipocyte size 
correlates with insulin resistance (IR) and hyperglycemia, and also depots with 
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large adipocytes show increased inflammation and susceptibility to cell death 
(66, 67). Meanwhile, SAT expands via both hypertrophy and hyperplasia, which 
is believed to be protective as smaller, newer adipocytes are more insulin 
sensitive and have enhanced storage capacity (64). Two recent rodent studies 
showed that VAT expands first in response to a high fat diet (HFD), eventually 
reaching a maximum capacity, while SAT continues to expand (68, 69). Upon 
reaching maximum capacity, adipocyte dysfunction results in increased lipid 
circulation, which is detrimental to metabolic homeostasis (70). This will be 
discussed in further detail in the next section.  
Ectopic lipid deposition 
       Adipose tissue expansion is typically sufficient to meet the requirements of 
excess energy storage. However, this adaptation is only viable up to a certain 
point when adipocytes fail to cope. This state is characterized by endoplasmic 
reticulum (ER) stress and mitochondrial dysfunction and results in increased 
intracellular and systemic levels of adipokines, free fatty acids and inflammatory 
mediators, which together drive adipocyte dysfunction (71). Lipogenesis is 
significantly reduced, as shown by the reduced expression of key lipogenic 
genes such as the adipogenic master regulator PPARγ (72). Conversely, there is 
an increase in lipolytic activity and lipid spillover from apoptotic adipocytes (67). 
The inability of AT to adequately store TAG results in ectopic deposition in other 
tissues such as liver and muscle. 
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        Muscle is a highly metabolically active tissue and is the major site of insulin 
stimulated glucose uptake, accounting for 75% of glucose clearance (73). Similar 
to adipose tissue, this is GLUT4-dependent, although exercise-induced, insulin-
independent expression of GLUT4 can also improve glucose clearance (74). 
Glucose is subsequently converted to glycogen and stored as a readily 
accessible source of energy. Once these glycogen stores are depleted, as is the 
case with exercise, there is a shift to glycolysis of fresh glucose taken up from 
the circulation (75). Muscle also stores a small amount of TAG as yet a third 
source of energy; however, increased circulating FFA in obesity causes excess 
deposition and an increase in TAG. Paradoxically, this phenomenon is also 
observed in endurance athletes with an active lifestyle (76). In obese patients, 
this increased lipid deposition is believed to promote IR in the muscle, impairing 
glucose clearance and contributing to a state of hyperglycemia (77).  
        In the liver, lipids are typically stored in hepatocytes only during fasting 
conditions; however, obesity increases hepatic lipid stores (78). This is thought to 
stem from increased circulating FFAs, and the resulting lipid accumulation has 
been associated with hepatic dysfunction, inflammation and ER stress (79). This 
pathological state called non-alcoholic fatty liver disease (NAFLD) can contribute 
to the development of type 2 diabetes (T2DM) if lipid accumulation goes 
unchecked (80). Fatty liver or steatosis is the first step on a spectrum of liver 
disorders that could result in cancer. The next step, non-alcoholic steatohepatitis 
(NASH), is promoted by prolonged steatosis, inflammation, cell death and 
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fibrosis. NASH predisposes the liver to cirrhosis, which is a high risk factor for the 
development of hepatocellular carcinoma (81).  However, the spectrum of 
NAFLD is beyond the scope of this thesis and we will focus on the pathology of 
T2DM instead.  
Insulin resistance and Type 2 Diabetes 
        Thus far, obesity has been characterized as an insult on the human body, 
with resulting sequelae associated with the metabolic syndrome. The body of 
work herein focuses on those factors that cause T2DM. T2DM is characterized 
by the inability to maintain fasting blood glucose levels within the normal range of 
4-6 mM, resulting in hyperglycemia, hyperinsulinemia and dyslipidemia. The T2 
diabetic state is also associated with a host of complications such as retinopathy, 
nephropathy and cardiovascular complications (82). Although there is a 
consensus that obesity predisposes one to develop T2DM, the underlying 
molecular mechanisms are still under rigorous investigation. A focal point for this 
research is the shift from insulin sensitivity to IR of insulin targets.  
        As discussed previously, adipocyte dysfunction and ectopic lipid deposition 
in muscle and liver are some of the factors believed to drive IR. In muscle, 
although TAG deposition is increased, it is increased intramyocellular DAG 
accumulation that is concomitant with IR and impaired glucose uptake (83, 84). 
These studies showed DAG signaling activates a novel PKC (nPKC) isoform 
PKCθ that blocked IRS-1-associated PI3K activity, and the data were later 
confirmed with human studies (85, 86). One mechanism proposed for hepatic 
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insulin resistance is an increase in pyruvate carboxylase activity due to increased 
levels of hepatic acetyl CoA derived from WAT-lipolysis. This results in the loss 
of insulin’s ability to suppress HGP, resulting in hyperglycemia (87).  Short chain 
FFAs can also inhibit glucose-stimulated insulin secretion by reducing glucose 
oxidation and thus reducing the ATP/ADP ratio (88). 
        Hyperglycemia triggers an increase in insulin secretion; however, the 
inability of target tissues to respond adequately creates a sustained feedback 
loop. This puts a strain on insulin-secreting β-cells, causing islet hyperplasia and 
a hyperinsulinemic state. Eventually, lipotoxicity, glucotoxicity, increased 
oxidative stress and inflammation result in β-cell failure (89, 90). Adipose tissue 
inflammation is also hypothesized to be an initiating factor in the development of 
IR (32). However, recent data from our lab suggests insulin itself is a driver of 
adipose tissue inflammation, therefore hyperinsulinemia is an early step in the 
development of obesity-associated diabetes (91). Whether inflammation is the 
chicken or the egg remains to be elucidated. Adipose tissue inflammation will be 
discussed in further detail in Part 2. 
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Figure 1.3 – Lean insulin sensitive versus Obese insulin resistant 
 
 
Figure 1.3 - Lean insulin sensitive versus obese insulin resistant 
Increased caloric intake usually combined with a sedentary lifestyle results in 
increased energy storage in the form of fat in adipose tissue. Adipocytes undergo 
hypertrophy and proliferation to cope with excess lipid, eventually leading to 
adipocyte dysfunction, increased lipolysis and ectopic lipid deposition in other 
tissues such as liver and muscle. This is associated with decreased insulin 
sensitivity and hyperglycemia resulting from increased hepatic glucose output. 
These sequelae define the type 2 diabetic state in the context of obesity. 
 
 
 
 
 
 
 
	  
23	  
PART 2: Inflammation and insulin resistance 
        The adipose tissue of obese diabetic patients and rodents has been 
characterized as being in a state of chronic low-grade inflammation, with 
increased cytokine expression and immune cell accumulation, particularly 
macrophages. This has prompted speculation on the role of inflammation in the 
development of insulin resistance and T2DM. Part 2 will focus on the current 
understanding of how inflammation is involved in the regulation of adipose and 
liver function.  
Immunometabolism 
Adipose tissue inflammation  
        The immune cell population of AT is the second largest after adipocytes 
themselves and therefore plays an important role in maintaining AT homeostasis. 
Furthermore, AT has increasingly been recognized as an important organ that 
integrates metabolic, endocrine and immune functions that affect systemic 
homeostasis as well (92). Resident AT immune cells span almost the entire 
spectrum of innate and adaptive immune cells, and in the lean healthy state they 
carry out general housekeeping functions including immune surveillance and 
clearance of apoptotic debris (93). In acute inflammation, the typical immune 
response in to an insult involves resident macrophage and mast cell secretion of 
cytokines and chemokines. This attracts neutrophils first, then macrophages and 
lymphocytes from the circulation, which clear the inflammatory agent and 
	  
24	  
affected cells (94). Antigen presenting cells (APCs) then facilitate the transition 
from innate to adaptive response carried out by B and T lymphocytes (95). This 
generally results in increased local and systemic levels of chemokines and 
cytokines typical of sepsis. Obesity induces an immune response in AT, although 
it is defined as chronic low-grade inflammation that displays modest increases in 
circulating proinflammatory cytokines without the clinical indications of 
inflammation (96).  
        Though less severe, this low-grade inflammation has been reported to have 
significant effects on whole body metabolism and the development of IR. The first 
evidence of this was the rat study by Feingold et al, which showed increased 
blood glucose levels with administration of the proinflammatory cytokine tumor 
necrosis factor alpha (TNFα) almost 30 years ago (97). Later studies showed that 
obese rodents and humans have elevated TNFα levels, and that knockout (KO) 
mice or mice administered with neutralizing antibodies against the protein had 
improved insulin sensitivity (98-100). Furthermore, evidence that obesity 
stimulated activity of the canonical inflammatory nuclear factor kappa B (NF-κB) 
pathway can drive IR helped strengthen the hypothesis of a metabolism-
inflammation connection (101, 102). Finally, these data together with the 
implication of another important class of proinflammatory signaling molecules, 
the c-Jun N-terminal kinases (JNK), served as the foundation for the field of 
immunometabolism (103, 104).  
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        AT immune cell composition and number is significantly altered by obesity, 
and in turn the immune response and function of AT is changed. Specifically, 
there is an increase in number and activity of macrophages, mast cells, B and T 
lymphocytes, and neutrophils, while a decrease in the number of other cell types 
such as eosinophils and subsets of T lymphocytes is observed (94). This shift of 
balance is typically observed in VAT rather than SAT, lending weight to the 
argument that VAT immune derangement is an important initiator of IR and 
T2DM (105). However, an acute decrease in fat mass such as that induced by 
caloric restriction also appears to trigger AT inflammation (106). This could be 
explained by increased AT lipolysis and secretion of lipid signaling molecules that 
activate or recruit AT immune cells (107).  
        The unequivocal immune response in AT in response to changes in energy 
balance suggests an evolutionary adaptation linking metabolism and 
immunology. Indeed the heavy presence of immune cells in AT suggests 
immunological control of this energy store (93). For example, adipokines and 
FFA release from perinodal AT (PAT) can control activation and proliferation of 
lymphocytes, and conversely, activated lymphocytes can induce lipolysis in PAT 
to fuel an immune response (108). One hypothesis that has arisen to explain this 
phenomenon is the ‘energy-on-demand hypothesis’. It offers the argument that 
AT inflammation and IR raise circulating nutrient levels, allowing rapid access to 
energy to mount an immune response against bacterial pathogens. On the other 
hand, parasite infestation requires starving the parasite by sequestering 
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nutrients. The diverse immune cell population therefore serves to alternate 
between these two states depending on the threat (109). Regardless of whether 
this is the case, AT inflammation continues to be a fertile area for research due to 
the number of different immune cells involved, particularly macrophages. Our 
understanding of the contribution of each of these cell types will be reviewed in 
next few sections of this chapter. 
Myeloid cells 
Adipose Tissue Macrophages 
       In lean rodents, adipose tissue macrophages (ATMs) constitute the largest 
number of AT immune cells, accounting for 10-15% of cells in VAT and rising to 
as much as 50% with obesity (110, 111). While lower in humans, the expansion 
of this population with obesity is still significant: from 4% to 12% (112). Further 
studies showed that this increase was associated with visceral obesity and the 
development of atherosclerosis, IR and hepatic dysfunction (113, 114). Adipocyte 
size and stromal vascular fraction (SVF) expression of pro-inflammatory 
elements such as TNFα also correlate with ATM infiltration (115, 116). 
Conversely, weight loss was shown to reduce the number of ATMs (117). 
However, without identifying the relevant macrophage phenotype involved, the 
link between ATM accumulation and IR cannot readily be deduced.  
        Ever since Weisberg et al showed that obesity induced ATM accumulation 
in rodents is a result of infiltrating macrophages from the circulation, this view has 
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been widely accepted (110). Other groups have reported on potential chemokine 
signals that recruit macrophages to obese AT, driving inflammation and IR. Most 
of the data points toward monocyte-chemoattracting protein 1/chemokine C-C 
motif ligand 2 (MCP-1/CCL2), which is secreted by adipocytes and binds the 
CCR2 receptor on macrophages to stimulate migration (110, 118, 119). Data 
demonstrated that MCP-1 overexpression promoted ATM accumulation, AT 
inflammation, hepatic steatosis and IR, strengthening this observation. 
Conversely, a dominant negative mutant attenuated these effects (120). 
Furthermore, there are also data to suggest other targets such as CCL3, CCL5, 
CCL7, CCL8, CCL11 and CCL13 are responsible (121-123). Chapter 2 will show 
evidence that MCP-1 is important for inducing local macrophage proliferation, 
which has been disregarded as a significant source of ATMs until recently. 
M1 and M2 ATMs 
        Macrophages are innate immune cells derived from the pool of mononuclear 
phagocytes generated in the bone marrow (124).  Depending on the nature of the 
immune response, their lifespan can vary from hours to years (125). Resident 
tissue macrophages are closely related to dendritic cells (DC). However they are 
distinguished by their expression of Fc receptors, F4/80 and CD11b upon 
differentiation from circulating monocytes (126). Macrophages have a number of 
important duties that range from serving as sentinels that phagocytose invading 
pathogens, to tissue remodeling after injury and scavenging dead cells and 
detritus (127, 128). There are a number of macrophage populations in the body, 
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typically named for their anatomical location such as microglia in the brain, 
alveolar macrophages in the lung, osteoclasts in bone, histiocytes in interstitial 
connective tissue and Kupffer cells in the liver (126).  Despite their location and 
phenotypic differences, they all perform macrophage-like functions with 
appropriate stimulation (129). Still, macrophages can further be described by 
their phenotypic function: M1 or classically activated, M2 or alternatively 
activated, regulatory macrophages, tumor associated macrophages, and others. 
M1 macrophages mediate host defense, antitumor immunity and inflammatory 
responses, whereas M2, regulator and tumor associated macrophages suppress 
those functions (130).  However, in the context of obesity-stimulated AT 
inflammation and IR, M1 and M2 seem to be the most important players (32).  
        Polarization of macrophages to the M1 phenotype involves pathogen- and 
damage-associated molecular patterns that synergize with interferon-γ (IFNγ). 
This results in the production of reactive nitrogen and oxygen species, which 
have antimicrobial properties (130). In vitro, bone marrow derived macrophages 
(BMDMs) can be induced to M1 polarity by stimulating with proinflammatory 
factors such as bacterial polysaccharides (LPS), IFNγ and granulocyte-
macrophage colony-stimulating factor (GM-CSF) (130). M2 polarization on the 
other hand is facilitated by anti-inflammatory cytokines interleukin-4 (IL-4), IL-10 
and IL-13, and macrophage colony-stimulating factor (M-CSF), which activate the 
signal transducer and activator of transcription 6 (STAT6) program. These 
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suppressor macrophages are involved in the antiparasitic response, wound 
repair and tissue remodeling (126, 130).     
        Lean adipose tissue is predominantly populated by anti-inflammatory M2 
macrophages, which secrete IL-10 and IL-1 receptor antagonist (IL1Ra), and 
they express M2 antigens CD206, Cd209 and CD301 as well as arginase 1 
enzyme, which blocks inducible nitric oxide synthase (iNOS) activity (32, 109). 
They carry out housekeeping functions that maintain AT homeostasis such as 
extra cellular matrix (ECM) remodeling, clearing cellular debris, regulating 
thermogenesis and preadipocyte proliferation and differentiation (109, 131, 132). 
Obesity induces a shift from M2 to M1 by decreasing the expression of important 
M2 maintenance factors such as IL-4 and IL-13 while increasing the expression 
of proinflammatory markers such as F4/80, CD11c, TNFα and IL-6 (115). These 
macrophages are recruited from the circulation rather than conversion of the 
resident M2 population (133). Unlike M2 macrophages that are diffusely located 
in AT, M1 macrophages tend to aggregate around necrotic adipocytes in crown-
like structures (CLS) and take up lipids to become foam cells. Furthermore, lipid 
signaling is also thought to play a role in the accumulation and polarization of M1 
macrophages (134). Chapter 4 will focus on the role of CLS macrophages in lipid 
buffering and how it affects systemic insulin sensitivity.  
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M1/M2 axis in insulin resistance  
        The presence of M1 ATMs is strongly associated with systemic 
inflammation and IR, and there is also evidence showing that ablation of this 
population is protective (135, 136). A number of mechanisms explaining this 
relationship have been proposed including recruitment and activation of other 
immune cells, TNFα-mediated inhibition of insulin signaling, and increased 
collagen expression leading to fibrosis (135, 137-139). The polarization of 
macrophages from M2 to M1 is driven by a number of different factors such as 
LPS, which binds to toll-like receptor 4 (TLR4), a member of a pattern recognition 
receptor family that activates an innate immune response against pathogens. 
Obese rodents and humans exhibit increased systemic LPS levels, and 
interfering with TLR4 signaling ameliorates ATM accumulation and M1 
polarization (140, 141). Lipid spillover from dysfunctional adipocytes also shifts 
macrophage polarity as saturated FFAs can also bind TLR4 as well as induce ER 
stress and inflammasome activation (142-144). Additionally, evidence suggests 
the important adipokine adiponectin has M2 polarizing effects. The reduced 
levels observed with increasing obesity could be another contributing factor to 
the M2 to M1 shift (145). 
        Though macrophages can exist as either M1 or M2, and this polarization 
can be recapitulated in vitro, closer inspection of in vivo populations suggests a 
continuum rather than a dichotomy. ATMs from both rodents and humans can 
simultaneously express F4/80 and CD11c, which are M1 markers, as well as 
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CD206 and CD301 (mannose receptor and Mgl1/2), which are M2 markers (146, 
147). Additionally, human ATMs also exhibit decreased expression of some M1 
markers while increasing the expression of the M2 marker lymphatic vessel 
endothelial hyaluronan receptor 1 (LYVE1) with obesity. Furthermore, these 
macrophages are also capable of secreting both pro- and anti-inflammatory 
factors (148). Interestingly, ATMs have also been shown to repolarize from one 
state to another. Switching rodents from a HFD to a normal diet can shift polarity 
back to M2, a change that is mimicked by adiponectin as well as administration 
of omega-3 FFAs (149-151). Thus, although useful for understanding 
inflammatory status of AT at a specific time, the M1/M2 classification is an 
oversimplification that should be approached cautiously.  
Dendritic cells 
        DCs share a common progenitor with macrophages and act as the primary 
APCs that present antigens to T cell receptors via major histocompatibility 
complexes I and II (MHCI, MHCII), thus facilitating the innate to adaptive 
immunity transition (152). They are also involved in promoting helper T cell 1 
(Th1) differentiation and the proliferation of CD8+ and natural killer cells. These 
responses are driven by cytokines IL12 and IL15, which are produced by DCs 
(95). Their identification and study in AT is complicated by the fact that they 
share a common primary marker CD11c with proinflammatory M1 macrophages. 
In flow cytometry, this is countered by defining macrophages as 
F4/80+CD11b+CD11c+ and DCs as F4/80-/lowCD11b-CD11C+ (153). In mice, HFD 
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feeding increases DC counts in AT, while humans exhibit increased levels of DC 
antigens in obese SAT and demonstrated ability of isolated cells to induce Th17 
cell differentiation. This creates a proinflammatory environment that favors an M1 
polarization of ATMs (154).  
Mast cells 
        Mast cells act as first line of defense against pathogens and maintain a 
heavy presence in barrier layers such as the mucosa and the skin. However, 
asthma, allergies and anaphylaxis responses are also associated with the 
uncontrolled activation of these cells (92). Once activated, they secrete a number 
of inflammatory factors including proteases, histamine, lipid mediators, and pro- 
and anti-inflammatory cytokines (155). AT mast cells are increased by obesity, 
and depletion of this population reduces ATM infiltration, prevents DIO and 
improves insulin sensitivity. Interestingly, data suggests these effects are 
mediated by IL-6 and IFNγ, affecting body weight and adiposity instead of AT 
inflammation (156).  
Neutrophils 
        Neutrophils are the first immune cells recruited to a site of inflammation or 
damage and are responsible for coordinating acute inflammatory responses. 
They are phagocytes and contain cytoplasmic granules of biologically active 
molecules such as myeloperoxidase (MPO), which is important for antimicrobial 
defense (92). Additionally, they secrete chemoattractants that recruit other 
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immune cells including DCs, macrophages and lymphocytes (157). Obese 
individuals have elevated plasma levels of neutrophil markers like MPO, and 
HFD feeding causes a transient (1week) 20-fold increase in AT neutrophil 
number preceding ATM infiltration (133, 158, 159). Neutrophil elastase has also 
been implicated in IR, potentially via the degradation of IRS-1 or TLR activation 
(160). 
Eosinophils 
        These granulocytes are involved in the antiparasitic response and secrete a 
host of cytokines, including IL-4 and IL-13, which mediate Th2 immunity (161). 
They are responsible for 90% of AT-associated IL-4 expression despite being 
present at very low numbers. They have also been linked to the M2 polarizing 
effects of IL-4 and IL-13, and their obesity-induced depletion is associated with 
the development of IR (162). However, administration of exogenous IL-4 can 
improve insulin sensitivity, further strengthening the idea of eosinophils playing a 
beneficial role (163). 
Lymphocytes 
CD4+ T cells 
        T cells are important for driving adaptive immunity and are classified as 
either CD4+ or CD8+ based on the expression of these two surface markers 
(92). CD4+ cells can be further subdivided into subclasses including but not 
limited to Th1, Th2, Th17 and regulatory T cells (Tregs) depending on which 
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cytokines they produce (164).  Obesity increases the number of Th1 cells, which 
secrete the proinflammatory cytokine interferon gamma (IFNγ). This cytokine 
polarizes ATMs to M1, thus promoting AT inflammation and IR. Indeed IFNγ 
deletion or modulating CD4+ cells into Tregs protects mice from these 
derangements (165, 166). The increase in Th1 cells is also accompanied by the 
decrease in Th2 cells, which maintain macrophages in an M2 state by secreting 
the anti-inflammatory cytokines IL-4, IL-5 and IL-13. Therefore maintaining an 
appropriate Th1/Th2 ratio is an important aspect of preventing AT inflammation 
(166). 
CD8+ T cells 
        CD8+ T cells are responsible for the antiviral response, and in addition to 
cytokines, they also release cytolytic factors (92). Similar to CD4+ cells, CD8+ 
infiltration is significantly increased with obesity and precedes macrophage 
infiltration. They are also responsible for polarizing macrophages to the M1 
phenotype as shown in vitro and in vivo (167).  Furthermore, adoptive transfer of 
CD8+ cells into CD8-deficient rodents increases the M1 ATM polarization, 
whereas ablating this cell population in obese rodents ameliorates AT 
inflammation and prevents the development of IR (166, 168). 
Th17 cells 
        Typically involved in autoimmune pathogenesis, increased cell counts and 
associated cytokines IL-17 and IL-23 can be found in obese patients regardless 
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of insulin sensitivity status. This is accompanied by a concomitant decrease in 
Tregs, which are responsible for regulating the action and proliferation of Th17 
cells (169-171). The discovery of an increase in this cell population in both 
diabetic and non-diabetic obese subjects has likewise spawned two contradicting 
hypotheses. One argues that IL-17 promotes IR by blocking IRS-1 signaling 
through JNK activation (172), while the other suggests that IL-17 prevents weight 
gain and decreases fasting glucose (169). Further investigation is warranted to 
tease out the actual role of Th17 cells in obesity and T2DM. 
Regulatory T cells 
        Tregs have a unique cell marker signature CD4+CD25+Foxp3+. They are 
responsible for suppressing inflammation, thereby allowing for a controlled 
immune response by antagonizing Th1 and Th17 responses (92). In obesity, AT 
Treg numbers are decreased along with anti-inflammatory cytokine IL-10, 
causing local and systemic pro-inflammatory cytokine presence, which promotes 
IR. Administration of recombinant IL-2 is sufficient to reverse these insults by 
stimulating an increase in Tregs (173). The beneficial role of Tregs is thought to 
stem from their ability to dampen the Th1 response in AT and prevent M1 
polarization of ATMs (174).  
Natural Killer T cells 
        NKT cells respond to lipid antigens presented by CD1d rather than peptide 
antigens presented by MHCI or MHCII and can participate in both Th1 and Th2 
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responses since they secrete both pro- and anti-inflammatory cytokines (95, 
175). Given their dual nature, it is not surprising that there are conflicting reports 
of their role in AT inflammation and associated IR. Rodent studies in which this 
cell population is depleted in the context of diet induced obesity report beneficial, 
neutral and detrimental effects (175-180). More evidence is required to build a 
more cohesive understanding of these cells. 
B cells 
        Although B cells can act as APCs, their primary function is the production of 
antibodies to help target foreign antigens (92). Obesity induces an increase in the 
number of AT B cells and indeed B cell depletion has been shown to improve IR 
in obese rodents (166, 181). Furthermore, IgG2c antibodies are elevated in 
obesity, stimulate M1 polarization of ATMs in obese AT and can promote AT 
inflammation and IR in lean mice (166, 182). 
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Figure 1.4: Crosstalk between adipose tissue and liver 
 
	  
 
Figure 1.4 - Crosstalk between adipose tissue and liver 
A chronic low-grade inflammation characterizes the obese T2DM adipose tissue, 
especially in visceral fat. There is an increase in immune cell content and 
activation, particularly macrophages. These phagocytes also help in remodeling 
and debris clearance, as is the case with dead and dying adipocytes, which are 
unable to cope with excess lipid storage. Under healthy conditions, insulin acts 
on the liver to lower postprandial glucose production. Macrophage infiltration is 
associated with increased cytokine production and impaired systemic insulin 
sensitivity. Kupffer cell activation has also been implicated in dysregulated 
hepatic glucose production. 
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Inflammation in other tissues 
Liver  
        As mentioned earlier, hepatocytes are the parenchymal cell type of the liver, 
however there is also a large immune cell population. This includes 
macrophages, T and B lymphocytes, DCs and NKs (183). In the context of 
obesity and IR however, macrophages are the most studied population. Kupffer 
cells (KCs) are resident macrophages in the liver, making up 80-90% of all tissue 
macrophages and over 10% of the liver cell population (184). Their main 
functions include phagocytosis of microbes and other toxic agents in the 
circulation and serving as APCs (185). Exposure to these agents results in 
activation of KCs and subsequent production of pro-inflammatory mediators such 
as cytokines and chemokines. These contribute to immune cell recruitment to the 
liver, but can also cause hepatic toxicity and impairment of liver function (186-
189).  
        Unlike AT, obesity does not increase KC number in the liver, but rather their 
activation state changes. Similar to AT however, in lean individuals, KCs have an 
M2 polarity, and perform tissue homeostasis functions (190). In obesity, the 
development of NAFLD and hepatic IR are associated with increased production 
of inflammatory cytokines such as TNFα, IL-6 and IL-1β by KCs (191, 192).  
Rodent studies show that KCs are activated by lipid and cholesterol derivative 
overload, and isolated KCs from HFD-fed mice are also more responsive to LPS-
induced activation compared to those from chow-fed mice (184). On the other 
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hand, alternative activation of KCs to an M2 phenotype can prevent insulin 
resistance as well as delay the progression to NASH (192). There is evidence 
suggesting that obesity induces KCs or hepatocytes to produce MCP-1, which 
attracts monocytes that differentiate into hepatic macrophages and exacerbate 
hepatic inflammation and IR. However, whether these recruited macrophages 
become KCs is still unclear (193, 194). Chapter 5 will highlight the role of NF-κB-
mediated activation of KCs in the development of IR 
Skeletal muscle 
        Obesity-induced inflammation and macrophage infiltration has also been 
observed in murine skeletal muscle, particularly in inter-muscular adipose 
depots, though to a much smaller extent than AT or liver (110). Like ATMs and 
KCs, these macrophages appear to also be polarized to the M1 phenotype and 
are associated with increased muscle IR and expression of proinflammatory 
factors (110, 133). Furthermore, in human skeletal muscle there is a correlation 
between insulin sensitivity and the expression of M1 and M2 macrophage 
markers (195).  
Pancreas 
        In the pancreas, inflammation is associated with β cell failure, resulting in 
decreased insulin production and hyperglycemia (196). The presence of amyloid 
deposits, fibrosis, β cell apoptosis and macrophage infiltration in islets of T2DM 
patients together with increased cytokine and chemokine expression indicate 
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pancreatic inflammation is a driver of IR (197). Endocannabinoid activation of the 
inflammasome in macrophages has also been implicated in β cell loss (90). 
Finally, macrophage infiltration seems to precede the onset of T2DM, and the 
cytokine IL-1β appears to be the master regulator of immune cell recruitment 
(198, 199). 
Hypothalamus 
        Most recently, DIO has been linked with the development of inflammation in 
the hypothalamus, particularly the arcuate nucleus (ARC) (200). This is notable 
because the ARC is involved in regulating energy homeostasis by modulating 
food intake and energy expenditure (201). Inflammation in the ARC is thought to 
be FFA-associated, since FFAs can access the ARC through its fenestrated 
vascularization. These FFAs induce inflammation and neuronal injury, resulting in 
increased pro-inflammatory gene expression, leading to the accumulation and 
activation of resident macrophages (202). Although the initial mechanism of 
inflammation is still incompletely understood, understanding how ARC 
inflammation affects satiety and energy imbalance is a fertile area of research for 
developing obesity therapeutics (203).    
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PART 3: Targeting adipose and liver macrophages  
        In part 2 we discussed the role of inflammation, particularly adipose tissue 
macrophage accumulation, in the development of diabetes. This discovery has 
been a driving force for research into ways of curbing ATM accumulation and 
inflammation. These methods have largely taken a whole body approach of 
targeting macrophages. Part 3 will introduce these techniques and their 
limitations and describe a novel technique that achieves specific macrophage 
targeting in adipose tissue.  
Reducing macrophage infiltration and activation 
Cytokine depletion 
        Given the data implicating ATMs and AT inflammation in obesity-induced IR, 
preventing macrophage activation has emerged as an attractive investigative and 
therapeutic approach (204). In order to achieve this, pathways associated with 
macrophage recruitment and activation including cytokine and chemokine 
signals, receptors for inflammatory factors, and intracellular mediators of 
inflammation have been targeted. Most studies however, have focused on 
blocking cytokine action. The earliest report of this, from Hotamisligil et al, 
involved the administration of a neutralizing antibody against TNFα to obese rats. 
This resulted in an increase in insulin-stimulated glucose uptake in peripheral 
tissues (99). Following up on these results Uysal et al. generated whole-body 
TNFα KO mice and placed them on a HFD. They also generated whole-body 
	  
42	  
KOs on an ob/ob background to test the effects of genetically induced obesity. 
KO animals showed improved insulin sensitivity and lower circulating free fatty 
acid levels compared to the control groups. Furthermore, they obtained similar 
results by deleting the genes encoding the two TNFα receptors (100). However, 
these benefits could not be replicated in human trials, as systemic administration 
of the TNF inhibitor Etanercept resulted in reduced systemic levels of 
inflammatory factors without any improvement in insulin sensitivity in obese 
patients (205). This data suggests that local TNFα activity in AT rather than 
systemic activity is important for inflammation-driven IR.  
        A different study focused on CCR2, the receptor for the MCP-1 cytokine 
which stimulates macrophage recruitment (119). By genetically deleting CCR2 
and putting the mice on a HFD, Christiansen et al. were able to show CCR2 
deficiency attenuated the development of obesity and reduced ATM infiltration. 
This was accompanied by protection from hepatic steatosis and improved whole-
body glucose metabolism and insulin sensitivity. Additionally, there was a 
surprising reduction in food intake. To determine the effects of CCR2 blockade in 
already established obesity, they administered a receptor antagonist, which also 
reduced ATM numbers and improved insulin sensitivity. However, this was not 
accompanied by any changes in weight or hepatic steatosis (206). These results, 
though compelling, require careful interpretation. CCR2 appears to play a 
significant role in ATM accumulation and AT inflammation, but its additional effect 
on food intake confounds those of ATMs on insulin sensitivity. It should be noted 
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that the apparent function of CCR2 in appetite regulation might be tied to ARC 
inflammation in the hypothalamus (200).  
        Another cytokine that has been targeted in ATM recruitment and 
inflammation is osteopontin (OPN). Osteopontin is a glycophosphoprotein 
expressed by a variety of cell types, most notably macrophages, which is 
involved in a number of macrophage functions including cytokine expression, 
phagocytosis, migration and expression of iNOS (207). Importantly, DIO raises 
circulating and AT levels of OPN in murine models and obese humans exhibit 
similar increases in expression. These increases have been associated with the 
infiltration of macrophages into VAT (208-211). Global OPN KO mice fed a HFD 
have reduced macrophage infiltration into AT, decreased expression of 
inflammatory markers both locally and systemically, and improved insulin 
sensitivity without any effect on obesity (208). Using a neutralizing antibody, 
Kiefer et al. reported similar results, as well as attenuation of liver inflammation 
and steatosis, which they attribute to increased macrophage apoptosis (212). 
Interestingly, they also propose that OPN deficiency in the liver shifts lipid 
storage back to AT, thereby attenuating hepatic steatosis and decreasing hepatic 
glucose output (213). There are clear benefits to blocking OPN action in the 
context of obesity, however these whole-body studies do not address the specific 
role of OPN secreted from the ATMs. Chapter 3 will address this issue and 
present data on macrophage-specific OPN depletion.  
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Targeting intracellular mediators  
        Rather than interfering with the extracellular signal, some studies have 
instead focused on disrupting inflammatory signaling by genetically altering major 
intracellular drivers of inflammation, i.e., JNK and NF-κB (104, 214, 215). In the 
case of JNK, reciprocal bone marrow transplants were performed between 
whole-body KO mice and wild type mice (104). Using this technique serves two 
purposes: first, any developmental defects or confounding effects are avoided, 
and secondly only hematopoietic cells possess the genetic mutation leaving the 
rest of the system unaltered. In this way the role of macrophages can be 
addressed more specifically. On a HFD, chimeric wild type mice that received 
JNK-depleted bone marrow were protected from AT and liver inflammation and 
also exhibited improved insulin sensitivity (104). However, according to a 
different study, JNK deletion in the non-hematopoietic population is required for 
the insulin-sensitizing effects of hematopoietic JNK deletion (214). Since JNK 
was deleted in all myeloid cells, this approach still fails to address how ATMs are 
specifically involved. 
        Arkan et al took an approach that is more precise and strategically different 
by indirectly targeting the master regulator of inflammation NF-κB (215). They 
used the LyzM-Cre conditional KO system to attain macrophage-specific deletion 
of IκB kinase β (IKKβ), which activates NF-κB by phosphorylating its inhibitors 
and thus promoting their degradation. IKKb deletion conferred partial protection 
from systemic insulin resistance without significant changes in adiposity (215). 
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Although this technique appears to primarily offer macrophage-specific gene 
deletion, LyzM-Cre also deletes in neutrophils and dendritic cells, and therefore 
does not allow for a true distinction between myeloid cell types (216). 
Interestingly, LyzM-Cre-mediated deletion of the insulin receptor improves 
glucose metabolism and protects against obesity-induced inflammation (217).  
Macrophage depletion 
         Another approach toward ameliorating or preventing AT inflammation 
centers on reducing the macrophage numbers as a whole. In studies of obesity-
induced inflammation, hepatic steatosis and IR, several studies have reported on 
the effects of depleting macrophage populations (135, 192, 218-226). Two 
methods have been reported in this regard, with the first one focusing on the 
conditional ablation of activated CD11c+ macrophages (135). The system relies 
on CD11c promoter-driven transgenic expression of the simian diphtheria toxin 
receptor (DTR). Injecting mice with diphtheria toxin specifically induces apoptosis 
in cells expressing this DTR. CD11c+ depletion resulted in reduced macrophage 
infiltration, lower proinflammatory cytokine levels and normalization of insulin 
sensitivity in AT, muscle and liver in mice fed a HFD (135).  
        The second method involves the use of liposomes to deliver toxic 
compounds to circulating monocytes and tissue macrophages. The most 
commonly used chemical compound for liposome macrophage depletion is a 
bisphosphonate called clodronate. In solution, this compound is unable to cross 
the plasma membrane, however liposomes are actively phagocytosed by 
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macrophages and allow clodronate to accumulate to toxic levels within the cell, 
thus triggering apoptosis (227). Intraperitoneal injections are used to target ATMs 
in mice on a HFD, and results show reduced weight gain, de-repression of 
adipocyte thermogenesis and improvement in insulin sensitivity (221, 222, 226). 
However, most studies report on intravenous injection of clodronate liposomes to 
target Kupffer cells in the liver, with mostly positive results. KC depletion appears 
to decrease hepatic lipogenesis, thereby ameliorating hepatic steatosis and 
improving systemic insulin sensitivity (192, 219, 223, 224). Another study showed 
that KC depletion prevented obesity and AT inflammation, but once established 
there was no therapeutic effect on IR (220). Only one group has reported 
detrimental effects of KC ablation in the context of obesity, citing the loss of KC-
derived IL-10, which exacerbates HFD-induced steatosis and IR (218). 
Gadolinium (III) chloride is another compound used to deplete KCs via liposome 
delivery, and the beneficial results mimic those of clodronate, with the added 
effect of improved autophagy (225). 
        Given all the evidence up to this point, macrophages engage in numerous 
processes and functions involving different cells and environmental contexts. 
Therefore completely ablating this population is likely to create unintended 
effects that could confound our understanding of a particular sub-population. A 
more specific and less toxic method of targeting our macrophages of interest, 
providing the necessary precision and level of safety is required. 
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Glucan-encapsulated siRNA Particles (GeRPs) 
        Based on the reports above, our lab generated a tool that could fill the 
technological gap in ATM targeting. In collaboration with the laboratory of Gary 
Ostroff, we developed a novel method of delivering siRNA oligonucleotides 
specifically to macrophages for targeted gene knockdown (KD). (228). The 
system relies on the use of β-3, 1-D-glucan microparticles derived from baker’s 
yeast, loaded with an siRNA sequence against the gene of interest. The first 
generation included a tRNA core, polyethyleneimine (PEI) and an amphipathic 
peptide called Endo-Porter in the formulation (228). These glucan-encapsulated 
siRNA particles (GeRPs) were delivered orally, taken up by macrophages 
systemically and facilitated targeted gene KD of mitogen activated protein kinase 
kinase kinase kinase 4 (MAPK4) (228). Using this formulation, another group 
also achieved specific downregulation of a different gene in peritoneal 
macrophages after intraperitoneal injection (229). These initial studies provided 
proof of concept, and a second generation of particles with fewer components 
was developed, eliminating PEI and tRNA, while retaining Endo-Porter (230).    
        These new particles, though simpler, also show macrophage-specific 
downregulation of genes, as reported by our lab and another. Importantly, this 
KD is tissue specific, homing in on particular sub-populations of macrophages 
depending on the route of administration (90, 230-233). The specificity of GeRPs 
is conferred by the β-3, 1-D-glucan, which is recognized by the Dectin 1 receptor 
expressed by phagocytic cells (234). The Endo-Porter peptide is a transfection 
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reagent of low toxicity that binds siRNA, creating a stable nanocomplex that 
anchors siRNA in the particles and also catalyzes endosomal escape (230). 
Chapters 3,4 and 5 will provide detailed information on studies conducted in our 
lab targeting ATMs and KCs for GeRP-mediated gene KD in the context of 
obesity, including tissue specificity and effects on whole body metabolism.  
Project Goals 
In obesity, inflammation has been implicated in the development of insulin 
resistance and impaired glucose metabolism resulting in T2DM. Particularly, 
macrophage infiltration into adipose tissue and activation of liver Kupffer cells are 
believed to play important roles in this pathology. However, direct evidence to 
support ATM and KC involvement is incomplete due to the lack of a methodology 
that specifically ties the function of these macrophage populations to disrupted 
whole-body metabolic homeostasis. As such, the experiments described in this 
thesis are aimed at describing the role of resident tissue macrophages in the 
regulation of insulin signaling, the effect on energy homeostasis, and how 
the functions of adipose tissue and liver are altered.  
 
There are three major aims addressed in this thesis: 
1. To determine how macrophages accumulate in AT: What is the source 
of macrophage accumulation in obese adipose tissue? Are macrophages 
solely recruited from the circulation or do they proliferate locally in adipose 
tissue? 
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2. To determine how ATM-specific gene targeting affects systemic 
metabolic function: Does ATM-derived OPN promote impaired glucose 
metabolism? Is LPL important for ATM lipid buffering?  
3. To determine how Kupffer cell-specific targeting affects systemic 
metabolic function: How does targeted knockdown of NF-κB in Kupffer 
cells affect liver function? Does changing the activation state of Kupffer 
cells affect systemic insulin sensitivity in obesity?  
To answer these questions, studies in this thesis utilize in vitro and in vivo 
experimentation to determine the role of macrophages on whole body 
metabolsim. First, we discovered that in addition to infiltration, macrophages 
proliferate locally in VAT of genetic and diet-induced models of obesity. 
Importantly, MCP-1 was identified as the cytokine with a direct role in promoting 
proliferation, particularly in CLS (Chapter 2). OPN was also significantly 
upregulated in VAT and was associated with increased macrophage proliferation. 
By administering GeRPs loaded with siRNA against OPN via intraperitoneal 
injection, significant downregulation of OPN was achieved in ATMs. GeRP-
mediated knockdown of ATM-derived OPN resulted in improved glucose disposal 
and insulin signaling as determined by glucose and insulin tolerance tests as well 
as increased AKT phosphorylation and lipogenic gene expression in adipose 
tissue (Chapter 3). On the other hand, GeRP-mediated knockdown of LPL in 
ATMs resulted in the loss of AT foam cells which led to increased circulating FFA 
and a concomitant increase in hepatic glucose output and decrease in hepatic 
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insulin sensitivity (Chapter 4).  To assess the importance of Kupffer cell activation 
state on hepatic function, GeRPs were delivered to Kupffer cells via intravenous 
injection. Depletion of NF-κB by this method decreased inflammatory markers in 
the liver, which was associated with an improvement in insulin signaling and 
decreased hepatic glucose output (Chapter 5). These data show that initial 
accumulation of macrophages in AT might be an adaptive response to AT 
remodeling and lipid spillover. However, with increasing accumulation, a chronic 
low-grade inflammation develops, exerting detrimental effects that lead to insulin 
resistance. Similarly, activated Kupffer cells promote hepatic inflammation, 
dysfunction and insulin resistance.  
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CHAPTER II: Local proliferation of macrophages contributes to obesity-
associated adipose tissue inflammation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter is derived from an article of the same title published in the journal of 
Cell Metabolism. 
Amano, S. U., Cohen, J. L., Vangala, P., Tencerova, M., Nicoloro, S. M., Yawe, J. 
C., Shen, Y., Czech, M. P., and Aouadi, M. (2014) Local proliferation of 
macrophages contributes to obesity-associated adipose tissue inflammation. Cell 
Metab 19, 162-171 
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SUMMARY 
        Adipose tissue (AT) of obese mice and humans accumulates immune cells, 
which secrete cytokines that can promote insulin resistance. ATM are thought to 
originate from bone-marrow-derived monocytes, which infiltrate the tissue from 
the circulation. Here, we show that a major fraction of macrophages 
unexpectedly undergo cell division locally within AT, as detected by Ki67 
expression and 5-ethynyl-20 -deoxyuridine (EdU) incorporation. Macrophages 
within the VAT, but not those in other tissues (including liver), displayed 
increased proliferation in obesity. Importantly, depletion of blood monocytes had 
no impact on ATM content, whereas their proliferation in situ continued. 
Treatment with monocyte chemotactic protein 1 (MCP-1) induced macrophage 
cell division in AT explants. These results reveal that, in addition to blood 
monocyte recruitment, in situ proliferation driven by MCP-1 is an important 
process by which macrophages accumulate in the VAT in obesity. 
 
INTRODUCTION 
        Obesity can induce an insulin-resistant state in AT, liver, and muscle and is 
a strong risk factor for the development of T2D (32, 70). It is increasingly 
appreciated that accumulation of macrophages and other immune cell types in 
AT correlates with a chronic inflammatory state that ultimately impairs adipocyte 
function and may contribute to the development of insulin resistance (32, 110, 
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231, 235). Consistent with this theory, decreasing AT inflammation improves 
insulin sensitivity (231).  
        The origin of ATMs has previously been attributed to recruitment of blood 
monocytes into AT based on one study using irradiation followed by bone 
marrow transplant (110). Therefore, strategies to decrease ATM accumulation 
have been particularly focused on decreasing macrophage migration into the 
adipose tissue by depleting blood monocytes or genes encoding chemokines that 
attract macrophages into the AT (206, 208). However, studies using these 
approaches have shown modest and variable results. One interpretation could be 
that a process other than migration contributes to maintain or increase 
macrophage content in the AT. 
        Although mature mammalian cells have a reduced proliferative capacity, 
there is evidence that immune cells, including macrophages, can divide even at 
the adult stage (236, 237). Indeed, local macrophage proliferation has been 
demonstrated in kidney, atherosclerotic plaques, skin and lung in animals and 
humans (238-243).  Interestingly, it has been shown that in tissues, such as lung, 
that are shielded from radiation, resident macrophages remain completely host-
derived for at least 8 months despite reconstitution with donor marrow (239). 
These studies showed that resident macrophage proliferate in situ independently 
of bone marrow derived monocytes.  
        The present study was designed to determine whether significant 
macrophage cell division also occurs within epididymal AT in mice.  Indeed, a 
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significant fraction of ATMs in obese mice display active proliferation, as detected 
by incorporation of 5-ethynyl-2’-deoxyuridine into DNA, even when circulating 
monocytes are depleted. These results suggest the unexpected concept that 
local macrophage proliferation contributes to the overall macrophage 
accumulation and VAT inflammation in the insulin resistant state. 
 
MATERALS AND METHODS 
Animals, Diets and Treatments: 8 to 12 week-old male wild-type C57BL/6J 
(WT) and B6.V-Lepob/J (ob/ob) mice were obtained from Jackson Laboratory 
(Bar Harbor, Maine, USA) and maintained on a 12-hour light/dark cycle. Animals 
were given free access to food and water. C57BL/6J wild-type mice were fed a 
high-fat diet (45% calories from lipids; D12451; Research Diets Inc., New 
Brunswick, New Jersey) for 7 weeks beginning at 8 weeks of age. All other mice 
were fed normal chow diet (Prolab 5P76 Isopro 3000, LabDiet, St. Louis, 
Missouri, USA). Intraperitoneal GTTs were performed as previously described 
(Fitzgibbons et al., 2011). Animals were weighed, sacrificed by cervical 
dislocation, and adipose tissues (epididymal and inguinal depots), livers and 
spleen were harvested at age 7-14 weeks. For the in vivo EdU injection studies, 
8-12 week-old mice were intraperitoneally injected with 1 mg EdU in 200 µl 
phosphate-buffered saline (PBS) and three hours later mice were sacrificed by 
asphyxiation with carbon dioxide and immediately bled by cardiac puncture prior 
to tissue dissection. For the in vivo EdU drinking water studies mice were given 
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free access to water containing 1 mg/ml EdU and 2% sucrose to offset taste 
aversion. All procedures were performed in accordance with protocols approved 
by the University of Massachusetts Medical School’s Institutional Animal Care 
and Use Committee. See Supplemental Methods for animal procedures. 
  
Isolation of macrophages from adipose tissue SVF: Adipose tissue SVF cells 
were prepared from collagenase-digested adipose tissue. Briefly, epididymal or 
inguinal fat pads were mechanically dissociated using the gentleMACS 
Dissociator (Miltenyi Biotec) and digested with collagenase at 37°C for 45 
minutes in Hank’s buffered saline solution (HBSS) (Gibco, Life Technologies) 
containing 2% bovine serum albumin (American Bioanalytical) and 2 mg/ml 
collagenase (collagenase from clostridium histolyticum, Sigma). Samples were 
then filtered through 100 µm BD falcon cell strainers and spun at 300 g for 10 
minutes at room temperature. The adipocyte layer and the supernatant were 
aspirated and the pelleted cells were collected as the SVF. The cells were then 
treated with red blood cell (RBC) lysis buffer, and then stained for flow cytometry.  
Liver and spleen cell isolation: Liver cells were isolated as previously 
described (244). Briefly, the livers of freshly asphyxiated mice were perused with 
collagenase 4mg/ml in 1% BSA in HBSS via the inferior vena cava and/or portal 
vein until livers were blanched. Small incisions at the edges of the liver were 
made to assist in complete blanching. After several minutes of perfusion, livers 
were placed in collagenase solution at 37 deg C with gentle rocking for 20-30 
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minutes. The resulting cell digest was filtered through a 100um mesh filter and 
several 30g centrifugation steps pelleted out hepatocytes. The remaining cells 
were pelleted by centrifugation at 500g and washed several times with HBSS. 
The cells were treated with RBC lysis buffer and then stained for flow cytometry.  
Spleens were manually dissociated using the plunger of a 1 ml plastic syringe in 
cold HBSS. The resultant cell suspension was centrifuged at 500g and the cell 
pellet was treated with RBC lysis buffer. A portion of the splenocytes was then 
taken for flow cytometry staining.  
   
Flow cytometry: Cells were resuspended in PBS containing 1% BSA (FACS 
buffer) containing Fc block (clone 2.4G2, eBioscience, San Diego, California, 
USA) and allowed to block non-specific binding for 15 minutes at 4°C. Cells were 
then counted and incubated for an additional 20 minutes in the dark at 4°C with 
fluorophore-conjugated primary antibodies or isotype control antibodies. 
Antibodies used in these studies included: F4/80-APC (clone Cl:A3-1, AbD 
Serotec, Raleigh, North Carolina, USA), CD11b-PerCP-Cy5.5 (clone M1/70), Gr-
1-APC-Cy7 (clone RB6-8C5), Siglec-f-PE (clone E50-2440), Ly6C-PE-Cy7 (clone 
AL-21), Ki67-FITC (clone B56) and IgG1κ-FITC (clone MOPC-21, BD 
Pharmingen San Diego, California, USA), and CD11c-V450 (clone HL-3, BD 
Horizon, San Jose, California, USA).  For the EdU experiments, cells were 
surface stained according to manufacturer’s instructions. Following incubation 
with primary antibodies, cells were washed and fixed with 
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fixation/permeabilization buffer (eBioscience) and then permeabilized with 
permeabilization buffer (eBioscience). EdU was chemically conjugated to Alexa 
405 or Alexa 647 fluorophore according to the instructions of the manufacturer 
(Invitrogen). Sample data were acquired on a BD LSRII (BD Biosciences) and 
analyzed with FlowJo software (Tree Star). Sample data were initially gated on 
forward and side scatter, followed by a singlet cell gate, and then a gate to 
remove auto-fluorescent debris (see Figure S1 for complete gating scheme).  
 
Immunohistochemistry: Adipose tissue SVF cells were plated overnight on 
glass coverslips in complete DMEM and then fixed for 15 min at room 
temperature in 4% paraformaldehyde. Cells were washed twice with PBS 
containing 0.3% Triton x-100 (American Bioanalytical, Natick, Massachusetts, 
USA) and blocked with 10% normal goat serum and were then incubated with the 
following antibodies: rat anti-mouse F4/80 (AbD Serotec, Raleigh, North 
Carolina, USA; 1:50 dilution), and goat-anti-mouse Ki67 (Abcam, Cambridge, 
Massachusetts, USA; 1:200 dilution) overnight at 4°C. After washing, the cells 
were incubated with secondary antibodies (1:200 dilution) for 30 minutes at room 
temperature. Cells were mounted in ProLong Gold antifade reagent containing 
4',6-diamidino-2-phenylindole (DAPI)  (Molecular Probes, Eugene, Oregon, 
USA). Adipose tissue sections were blocked with 10% normal goat serum and 
were then incubated with anti-Ki67 antibodies and hematoxylin stained. Images 
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were captured on a Zeiss Axiovert 200M microscope using Axiovision software 
(Carl Zeiss, Thornwood, New York, USA).  
 
Isolation of RNA and Real Time PCR: RNA isolation was performed according 
to the Trizol Reagent Protocol (Invitrogen). cDNA was synthesized from 0.5-1 µg 
of total RNA using iScript cDNA Synthesis Kit (Bio-Rad) according to the 
manufacturer’s instructions.  For real time PCR, synthesized cDNA forward and 
reverse primers along with the iQ SYBR Green Supermix were run on the CFX96 
Real-time PCR System (Bio-Rad). The ribosomal mRNA, 36B4 was used as an 
internal loading control, as its expression did not change over a 24 h period with 
the addition of LPS or siRNA against the genes used in this study. Primer 
sequences used are as follows: 36B4 (5’-TCCAGGCTTTGGGCATCA-3’, 5’-
CTTTATCAGCTGCACATCACTCAGA-3’); mcp1 (5’-
GCTGGAGAGCTACAAGAGGATCACC-3’, 5’-
TCCTTCTTGGGGTCAGCACAGAC-3’); opn (5’- 
AGCAAGAAACTCTTCCAAGCAA-3’, 5’-GTGAGATTCGTCAGATTCATCCG-3’); 
il4 (5’-GGTCTCAACCCCCAGCTAGT-3’, 5’-GCCGATGATCTCTCTCAAGTGAT-
3’); mcsf (5′-GACTTCATGCCAGATTGCC-3′, 5′-GGTGGCTTTAGGGTACAGG-
3′)   
  
Statistical analysis: All values are shown as means ± SEM. Student's t-test for 
two-tailed distributions with equal variances was used for comparison between 
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two groups. Differences p ≤ 0.05 were considered significant. Statistical analyses 
were performed with Graph Pad Prism 5.  
 
RESULTS 
Macrophages proliferate locally within the adipose tissue 
        To confirm macrophage accumulation in AT of obese mice, we used 8 to 
12-week old genetically obese (ob/ob) male mice and their lean control wild-type 
(WT) littermates. Stromal-vascular fraction (SVF) from subcutaneous and 
visceral epididymal fat pads, which contains all cells of the AT except adipocytes, 
was stained with antibodies against macrophage markers, F4/80 and CD11b, an 
eosinophil marker, Siglec-f, and a neutrophil marker, Gr-1 and analyzed by flow 
cytometry. The macrophage population in the AT was defined as 
F4/80+/CD11b+/Siglec-f–/Gr-1–. Consistent with published studies, macrophage 
content was significantly increased in the epididymal adipose depot of ob/ob 
compared to WT mice (WT 140 ± 35 x103 vs. ob/ob 959 ± 69 x103 
macrophages/g of epididymal fat, p<0.001 and Figure 2.1A-B). The number as 
well as the percentage of macrophage was also increased in the subcutaneous 
AT of ob/ob compared to WT mice but to a lower extent than in epididymal AT 
(WT 109 ± 12 x103 vs. ob/ob 192 ± 31 x103 macrophages/g of epididymal fat, 
p=0.04 and Figure 2.1E).  
        To test whether ATM proliferation increases in the inflammatory setting of 
obesity, SVF cells were stained with an antibody against the proliferation marker 
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Ki67, which is a protein expressed during all active phases of the cell cycle (245). 
Ki67 signal was detected in approximately 2.3% of epididymal ATMs of lean WT 
mice, and in 10% of ATMs of ob/ob mice (WT 7.6 ± 3.2 x103 vs. 94 ± 7 x103 
macrophages/g of epididymal fat, p<0.001 and Figure 2.1C-D). The percentage 
of Ki67+ macrophages was also increased in subcutaneous adipose tissue from 
ob/ob compared to WT mice (Figure 2.1F).  However, the number of Ki67+ 
macrophages was lower in subcutaneous compared to epididymal fat pad in 
ob/ob mice (subcutaneous 20.0 ± 3.3 x103 vs. epididymal 94 ± 7 x103 
macrophages/g, p<0.001).  
        We next measured the proliferation rate of ATMs in mice with diet-induced 
obesity. Mice were fed a high fat diet (HFD) for 7 weeks and SVF isolated from 
the epididymal fat pad was stained with antibodies against macrophages markers 
and Ki67. Similar to genetically induced obesity, diet-induced obesity increased 
macrophage content in the AT (Figure 2.2A-B). ATM number was significantly 
higher in SVF of epididymal AT in mice fed a high fat diet (HFD) compared to 
normal chow diet (ND) (ND 140 ± 35.103 vs. HFD 1,045 ± 131 x103 
macrophages/g of epididymal fat, p<0.001). More importantly, in mice fed a HFD 
17% of ATMs were Ki67+ compared to 3% in mice fed a ND (ND 7.6 ± 3.2 x103 
vs. HFD 183 ± 21 x103 macrophages/g of epididymal fat, p<0.001) (Figure 2.2 C-
D).  
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Fig 2.1 – Genetic Obesity induces macrophage proliferation in AT 
Figure 2.1 Genetic obesity induces macrophage proliferation in VAT  
(A-B) Percentage of CD11b+F4/80+ macrophages from SVF of WT vs. Ob/Ob. 
(C-D) Percentage of macrophages expressing Ki67 in VAT of WT vs. Ob/Ob 
mice; n=10. (E) Percentage of macrophages in SVF from SAT of WT vs. Ob/Ob 
mice. (F) Percentage of macrophages expressing Ki67 in SAT of WT vs. Ob/Ob 
mice; n=10. All graphs are expressed as mean ±s.e.m. Statistical significance 
was determined by Student’s t-test. ***P<0.001 
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Figure 2.2 – HFD induces macrophage proliferation in VAT 
 
Figure 2.2 HFD induces macrophage proliferation in VAT 
(A-B) Percentage of macrophages in SVF from VAT of mice fed a ND or a HFD 
for 10 weeks. (C-D) Percentage of macrophages expressing Ki67 in VAT of mice 
fed a ND or a HFD; n=18. All graphs are expressed as mean ± s.e.m. Statistical 
significance was determined by Student’s t-test. ***P<0.001 
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Macrophage proliferation contributes to adipose tissue inflammation 
independently of monocyte recruitment 
        To test this hypothesis that macrophages proliferate independently of 
monocyte recruitment, we depleted blood monocytes in ob/ob mice by 
intravenous (i.v.) injection of clodronate-loaded liposomes, which induce 
apoptosis once ingested by monocytes (227). ob/ob mice were given EdU in 
drinking water during monocyte depletion as depicted in diagram in Figure 2.3A. 
Thirty-two hours after EdU exposure, approximately 28% of macrophages were 
EdU+ in the AT of ob/ob mice injected with PBS-liposomes (Figure 2.3B-C).  
Eighty hours after EdU exposure, about half of the macrophages in the AT of 
ob/ob mice injected with PBS-liposomes had incorporated EdU (Figure 2.3B-C). 
Importantly, depletion of blood monocyte had no effect on macrophage 
proliferation as observed by the EdU incorporation in the epididymal AT of ob/ob 
mice injected with clodronate-liposomes (26% after 32 hrs. and 46% after 80 
hrs.) (Figure 2.3B-C).  
        We next analyzed the proliferative capacity of macrophages in the 
epididymal AT depot, where most of the macrophage expansion occurs in 
obesity, versus the subcutaneous AT depot (Figure 2.3D). EdU incorporation by 
macrophages was significantly higher in the epididymal AT of ob/ob compared to 
WT mice. However, no difference in EdU incorporation was observed in 
macrophages in subcutaneous AT of ob/ob compared to WT mice after 80 hours 
of EdU exposure (Figure 2.3D). This suggested that macrophage proliferation 
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plays a major role in epididymal AT macrophage expansion in obesity. It has 
been previously showed that CLS density is higher in visceral fat compared to 
subcutaneous depot in obese mice (246). Interestingly, microscopic analysis of 
epididymal AT section showed that EdU was mostly incorporated in 
macrophages in CLS (Figure 2.3E).  
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Fig 2.3 – ATMs proliferate independent of monocyte recruitment 
 
    
   
 
Figure 2.3 ATMs proliferate independent of monocyte recruitment 
(A) Schematic representation of experimental design. (B) Representative flow 
cytograms (C) and quantification (D) of EdU incorporation into ATMs during 32 
and 80 hrs. of exposure to EdU drinking water in PBS-Lipo-treated and 
monocyte-depleted Clod-Lipo-treated ob/ob mice; n=5 (E) VAT of ob/ob mice 
containing CLS stained with antibodies against F4/80 (red) and EdU (green). 
Nuclei were stained with DAPI (blue). 20x magnification images. The scale bar 
represents 40 µm. 
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MCP-1 stimulates adipose tissue macrophage proliferation 
        To investigate the mechanism by which obesity stimulates macrophage 
proliferation selectively in the AT, we measured, in AT and liver of lean (ND and 
WT) and obese (HFD and ob/ob) mice, the expression of multiple cytokines 
known to play a role in macrophage proliferation, IL-4 (239), M-CSF (242), and 
macrophage infiltration, OPN (208) and MCP-1 (120, 206)(Figure 2.4A-D). While 
IL-4 and M-CSF expression in the epididymal AT was either decreased or 
unchanged with obesity, OPN and MCP-1 expression was significantly increased 
in ob/ob mice or mice fed a HFD compared to control lean mice (Figure 2.4A-D).  
        As described in figure 1 and 2, macrophage proliferation was mainly 
increased in epididymal AT in obese compared to lean mice, therefore we next 
measured the expression of OPN and MCP-1 in this fat depot compared to 
subcutaneous AT and liver, where ATM proliferation is minimal (Figure 2.4E-F). 
Although OPN expression was unchanged in subcutaneous AT in obese 
compared to lean mice, it was significantly increased in liver (Figure 2.4E). In 
addition OPN expression was similar in liver and epididymal AT in mice fed a 
HFD (Figure 2.4E). In contrast, MCP-1 expression was significantly higher in 
epididymal AT compared to liver and subcutaneous fat in obese mice (Figure 
2.4F).  
        Although macrophage subpopulations in the AT may have overlapping 
marker expression profiles, it is generally thought that CD11c expression is 
characteristic of proinflammatory macrophage subtypes (247). Therefore, we 
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analyzed the rate of proliferation of proinflammatory (CD11c+) and anti-
inflammatory (CD11c-) macrophages (data not shown). We failed to observe any 
difference in the rate of proliferation of macrophage population subtypes. This 
suggests that obesity increases macrophage proliferation rate independently of 
their inflammatory state. 
        MCP-1 has been extensively described as a chemokine attracting 
macrophages from the blood to the AT in obese mice (120, 206). Thus, to test 
whether MCP-1 regulates ATM proliferation independently of macrophage 
recruitment, epididymal AT explants from ob/ob mice were treated with 1 and 10 
ng/ml of MCP-1 and EdU incorporation in ATM was measured by flow cytometry. 
10 ng/ml MCP-1 treatment significantly increased the number of macrophages in 
the AT explants independently of monocyte recruitment (Figure 2.4G). More 
importantly, MCP-1 treatment significantly increased the number of EdU+ ATMs 
(Figure 2.4H). These results suggested that MCP-1 could regulate macrophage 
proliferation in AT. We then compared the expression of MCP-1 in adipocytes 
and SVF from epididymal AT of mice fed a HFD. Although MCP-1 expression 
was high in both fractions, it was significantly higher in the adipocytes (Figure 
2.4I) 
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Fig 2.4 – MCP-1 stimulates macrophage proliferation in VAT 
 
 
 
    
Figure 2.4 MCP-1 stimulates macrophage proliferation in VAT 
il4 (A), mcsf (B), opn (C), and mcp-1 (D) expression was measured by RT-PCR; 
n = 5. (E-F) Expression of opn (E) and mcp-1 (F) in SAT, VAT, and liver from 
mice fed an ND or HFD for 7 weeks; n = 5. (M-N) Explants from VAT of five 
ob/ob mice were treated with 1 and 10 ng/ml of MCP-1 in presence of 10 mM of 
EdU for 48 hr. Graph represents the number of macrophages (G) and EdU+ (H) 
macrophages in explants. (I) Expression of mcp1 in adipocytes and SVF from 
epididymal AT of HFD fed mice; n = 5. Statistical significance was determined by 
Student’s t-test. ***P<0.001; **P<0.01; *P<0.05. 
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DISCUSSION 
       Macrophages have been shown to accumulate in massive numbers in the 
AT of obese mice and human subjects (110, 111). We confirmed that 
macrophages accumulate in AT of both genetically and diet induced models of 
obesity (Figure 2.1 and 2.2). FACS analysis showed an increase in both the 
percentage and number of macrophages in subcutaneous and visceral AT 
depots of obese mice; with VAT showing a more significant increase. These 
results confirmed that macrophages accumulate mostly in the epididymal AT in 
mice in response to obesity caused by either genetic mutation or a diet high in fat 
(Figure 2.1 and 2.2). Importantly, further analysis of the macrophage populations 
in these depots also revealed that they expressed the proliferation marker Ki67 in 
both lean and obese states. However, obese mice displayed an increase in Ki67 
expression that was concomitant with macrophage accumulation. In addition, this 
increase in Ki67 expression was more significant in the visceral compared to 
subcutaneous AT of obese mice (Figure 2.1 and 2.2). Collectively, these results 
show that macrophages express the proliferation marker Ki67 in the AT in mice 
and humans and to a higher degree in response to obesity in mice caused by 
either genetic mutation or a diet high in fat.  
        By performing irradiation and transplant studies Weisberg et al. 
demonstrated that ATMs are derived from the bone marrow, subsequently 
migrating to and differentiating in the AT (110). They concluded that the ATM 
population increases as a result of monocyte recruitment, but did not rule out 
	  
71	  
proliferation of resident macrophages. By utilizing clodronate-liposomes and EdU 
incorporation we found that macrophage proliferation is unaffected by depletion 
of blood monocytes (Figure 2.3). These results suggest that resident 
macrophages proliferate independently of monocyte recruitment. However, 
recently recruited macrophages may also proliferate in AT of obese mice since a 
recent study showed that 5% of labeled blood monocytes, transferred from donor 
into recipient mice, express Ki67 in the host AT two days after transfer (248). We 
also found that consistent with higher Ki67 expression in VAT than SAT, EdU 
incorporation was also increased in VAT but did not change in SAT of obese 
mice (Figure 2.3). This data is in line with the observation that obesity-induced 
macrophage accumulation occurs primarily in VAT (Chapter 1). It is also 
important to note that proliferating macrophages were localized to crown like 
structures, around dead and dying adipocytes (Figure 2.3). This implies a 
mechanism whereby the AT responds to adipocyte dysfunction by locally 
stimulating macrophage proliferation, in order to facilitate remodeling and 
clearing of debris. 
        In attempting to understand this mechanism of obesity-induced proliferation 
in AT, we measured the expression of cytokines IL-4, M-CSF, OPN and MCP-1, 
and found that only MCP-1 and OPN were significantly increased by obesity in 
VAT (Figure 2.4). However, OPN was increased in both VAT and liver, whereas 
MCP-1 was only increased in VAT, where we also see increased proliferation 
(Figure 2.4). This suggests a positive regulation between MCP-1 expression and 
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macrophage proliferation in mice. Furthermore, treatment of explants from Ob/Ob 
mice ex vivo elicited a strong proliferative response of ATMs. The MCP-1 
receptor CCR2 has also been shown to be mostly expressed in macrophages in 
CLS where most of proliferating ATMs were observed (115). These results 
suggested that MCP-1 released by adipocytes in CLS could stimulate 
proliferation of surrounding ATMs. Although proliferation may be regulated by 
multiple factors, MCP-1 plays a major role in regulating macrophage proliferation 
in the AT of obese mice. 
        In summary, we show here that macrophage proliferation within epididymal 
AT is a dynamic mechanism that increases with obesity. Given the high 
proportion of macrophages (about 50%) that incorporate EdU over 80 hours, 
proliferation therefore likely contributes significantly to the accumulation of 
macrophages and the inflammation of AT in obesity. At the molecular level, this 
study revealed MCP-1 as a potential stimulus for macrophage proliferation in 
obese adipose tissue. 
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Chapter III: Silencing osteopontin in adipose tissue macrophages regulates 
whole-body metabolism in obese mice 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter is derived from an article published in Proceedings of the National 
Academy of Sciences. 
Aouadi, M., Tencerova, M., Vangala, P., Yawe, J. C., Nicoloro, S. M., Amano, S. 
U., Cohen, J. L., and Czech, M. P. (2013) Gene silencing in adipose tissue 
macrophages regulates whole-body metabolism in obese mice. Proc Natl Acad 
Sci U S A 110, 8278-8283 
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• Figure 3.3 Osteopontin expression and siRNA test – RT-PCR analysis 
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•  Figure 3.4 GeRP mediated osteopontin knockdown – Knockdown 
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inflammatory gene expression was performed by Joseph Yawe.  
• Figure 3.5 Metabolic studies – The administration of GeRPs, subsequent 
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• Figure 3.6 Insulin signaling and adipocyte gene expression analysis – 
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• Figure 3.7 Osteopontin knockout animals. Joseph Yawe conducted all 
experiments in this figure with assistance from Pranitha Vangala during 
metabolic studies.  
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SUMMARY 
        Adipose tissue inflammation and infiltration by macrophages is associated 
with insulin resistance and T2DM in obese humans, offering a potential target for 
therapeutics. However, whether ATMs directly contribute to systemic glucose 
intolerance has not been determined. The reason is the lack of methods to ablate 
inflammatory genes expressed in macrophages specifically localized within AT 
depots, leaving macrophages in other tissues unaffected. Here we report that i.p. 
administration of siRNA encapsulated by glucan shells in obese mice selectively 
silences genes in epididymal ATMs, whereas macrophages within lung, spleen, 
kidney, heart, skeletal muscle, subcutaneous (SubQ) adipose, and liver are not 
targeted. Such administration of GeRPs to silence the inflammatory cytokine 
osteopontin in epididymal ATMs of obese mice caused significant improvement 
in glucose tolerance. These data are consistent with the hypothesis that 
cytokines produced by ATMs can exacerbate whole-body glucose intolerance. 
 
INTRODUCTION 
        The rapidly rising prevalence of obesity and T2DM over the past several 
decades has highlighted a pressing need to develop new therapeutics for these 
metabolic diseases (249). In obese human subjects, the inability to appropriately 
expand subcutaneous adipose tissue leads to ectopic lipid deposition in liver and 
muscle and may be an underlying cause of insulin resistance (70, 250, 251). It is 
well appreciated that infiltration and activation of macrophages in the visceral AT 
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correlate with a chronic inflammatory state. These macrophages secrete 
cytokines and other factors that could impair the ability of adipocytes to secrete 
beneficial adipokines or store lipid, leading to lipid deposition in nonadipose 
tissues and insulin resistance (32, 110, 252). Consistent with this concept, 
macrophage numbers in visceral AT correlate with systemic insulin resistance 
even in obese human subjects that are matched for body mass index (253, 254). 
In light of this evidence, it has been suggested that therapeutics that can 
attenuate visceral AT inflammation may alleviate the diabetic state (Chapter 1). 
        Despite abundant literature consistent with the paradigm that AT 
inflammation contributes to systemic insulin resistance and glucose intolerance, 
direct data actually addressing this issue is difficult to obtain. The limitation has 
been a lack of available methodology to ablate inflammatory genes expressed in 
macrophages specifically localized within AT depots while leaving these immune 
cells in other tissues unaffected. This was discussed in detail in chapter 1, as 
well as the introduction of a methodology designed to overcome this limitation i.e. 
GeRPs. We show here that in contrast to lean mice, in which i.p.-injected GeRPs 
are phagocytosed by macrophages throughout the body (228, 230), i.p. injection 
of GeRPs into obese mice results in their accumulation and silencing of genes 
mostly in macrophages found in the VAT. Under the same conditions, we could 
not detect GeRPs in these immune cells within other tissues.  
        Using this approach, we targeted the inflammatory cytokine osteopontin, 
whose expression is upregulated by obesity. It is also thought to play a role in the 
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development of insulin resistance in rodents and humans (208-211). Attenuation 
of OPN expression improved whole-body glucose tolerance. These results reveal 
i.p. administration of GeRPs as a unique tool to study the specific role of visceral 
ATMs in the development of insulin resistance induced by obesity. 
 
MATERIALS AND METHODS 
Animals: All mice were purchased from Jackson Laboratory. Mice were housed 
on a 12-h light/dark schedule and had free access to water and food. High fat 
diets were obtained from Research Diets: 45% kcal fat (D12451) and 60% kcal 
fat (D12492). All procedures involving animals were approved by the Institutional 
Animal Care and 
Use Committee at the University of Massachusetts Medical School. 
 
Preparation of Glucan Shells: β-1,3-D-glucan particles were prepared by 
suspending Saccharomyces cerevisiae (100 g of SAF-Mannan, SAF Agri) in 1 L 
of 0.5 M NaOH and heating to 80 °C for 1 h. The insoluble material containing 
the yeast cell walls was collected by centrifugation, suspended in 1 L of 0.5 M 
NaOH, and incubated at 80 °C for 1 h. The insoluble residue was again collected 
by centrifugation and washed three times with 1 L of water, three times with 200 
mL of isopropanol, and three times with 200 mL of acetone. The resulting slurry 
was placed in a glass tray and dried at room temperature to produce 16.2 g of a 
fine, slightly off-white powder.  
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Fluorescein labeling of Glucan Shells: Glucan shells (1 g) were washed with 
sodium carbonate buffer (0.1 M, pH 9.2) and resuspended in 0.1 L carbonate 
buffer. Then 5-(4,6-dichlorotriazinyl) aminofluorescein (Invitrogen; 1 mg/mL in 
ethanol) was added to the buffered glucan shell suspension (10% vol/vol) and 
mixed at room temperature in the dark overnight. Tris buffer (2 mM) was added, 
incubated for 15 min, and glucan shells washed with sterile pyrogen-free water 
until the supernatant was clear. The glucan shells were then flash-frozen and 
lyophilized in the dark.  
 
Preparation of GeRPs: To load siRNA in glucan shells, 3 nmol siRNA 
(Dharmacon) were incubated with 50nmoles Endo-Porter (EP; Gene Tools) in 30 
mM sodium acetate pH 4.8 for 15 min at room temperature in a final volume of 
20 µL. The siRNA/EP solution was added to 1 mg (∼109) of glucan shells and 
then vortexed and incubated for 1 h. The siRNA-loaded GeRPs were then 
resuspended in PBS and sonicated to ensure homogeneity of the GeRP 
preparation. GeRPs were kept at 4 °C. siRNA sequences used are as follows: 
Scrambled (SCR) (5’-CAGUCGCGUUUGCGACUGGUU-3’); anti-OPN1 (5’-
CAACUAAAGAAGAGGCAAAUU-3’); anti-OPN2 (5’-
CCACAUGGCUGGUGCCUGAUU-3’) 
 
GeRP Administration and Tissue Isolation: Five-week-old C57BL6 ob/ob male 
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mice were i.p. injected once a day for 5 or 10 d with 5.6 mg/kg GeRPs loaded 
with 2.1 mg/kg EP and 0.262 mg/kg siRNA. Twenty-four hours after the last 
injection, mice were killed and tissues were isolated and used for RT-PCR and 
microscopy. 
 
Metabolic Studies: Glucose and insulin tolerance tests were performed on ob/ 
ob animals at 5 or 10 d after GeRP treatment. Glucose (1 g/kg) and insulin 
(1 IU/kg) were administrated by i.p. injection. Blood samples were withdrawn 
from the tail vein at the indicated time, and glycemia was determined using 
glucometers (Bayer and alpha-trak). 
 
Isolation of Macrophages From Adipose Stromal-Vascular Fraction: 
Epididymal fat pads were mechanically dissociated using the gentleMACS 
Dissociator (Miltenyi Biotec) and collagenase digested at 37 °C for 45 min in 
HBSS (Gibco, Life Technologies) containing 2% BSA (American Bioanalytical) 
and 2 mg/mL collagenase (Sigma-Aldrich). Samples were then filtered through 
100-µm-diameter pore nylon mesh and centrifuged. The adipocyte layer and the 
supernatant were aspirated and the pelleted cells were collected as the stromal-
vascular fraction (SVF). The cells were then treated with red blood cell lysis 
buffer and washed in PBS and plated or directly harvested for further analysis.  
Isolation of RNA and Real-Time PCR: RNA isolation was performed according 
to the TRIzol Reagent Protocol (Invitrogen). cDNA was synthesized from 0.5 to 1 
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µg of total RNA using iScript cDNA Synthesis Kit (Bio-Rad) according to the 
manufacturer’s instructions. For real-time PCR, synthesized cDNA forward and 
reverse primers along with the iQ SYBR Green Supermix were run on the CFX96 
Real-time PCR System (Bio-Rad). The ribosomal mRNA 36B4 was used as an 
internal loading control be- cause its expression did not change over a 24-h 
period with the addition of LPS or siRNA against the genes used in this study. 
Primer sequences are as follows: 36B4 (5’TCCAGGCTTTGGGCATCA-3’, 5’-
CTTTATCAGCTGCACATCACTCAGA-3’); mcp1 (5’-
GCTGGAGAGCTACAAGAGGATCACC-3’, 5’-
TCCTTCTTGGGGTCAGCACAGAC-3’); opn (5’- 
AGCAAGAAACTCTTCCAAGCAA-3’, 5’- GTGAGATTCGTCAGATTCATCCG-3’); 
il4 (5’- GGTCTCAACCCCCAGCTAGT-3’, 5’- 
GCCGATGATCTCTCTCAAGTGAT-3’); il6 (5’-
TAGTCCTTCCTACCCCAATTTCC-3’, 5’-TTGGTCCTTAGCCACTCCTTC-3’); 
il10 (5’-CTGGACAACATACTGCTAACCG-3’, 5’-
GGGCATCACTTCTACCAGGTAA-3’); il1b (5’-GCAACTGTTCCTGAACTCAACT-
3’, 5’-ATCTTTTGGGGTCCGTCAACT-3’); cd11b (5’-
ATGGACGCTGATGGCAATACC-3’, 5’-TCCCCATTCACGTCTCCCA-3’); cd11c 
(5’-CTGGATAGCCTTTCTTCTGCTG-3’, 5’-GCACACTGTGTCCGAACTCA-3’); 
f4/80 (5’-CCCCAGTGTCCTTACAGAGTG-3’, 5’-GTGCCCAGAGTGGATGTCT 
-3’); cd68 (5’-GGACCCACAACTGTCACTCA-3’, 5’-
AAGCCCCACTTTAGCTTTACC-3’); ccr2 (5’-
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ATCCACGGCATACTATCAACATC-3’, 5’-CAAGGCTCACCATCATCGTAG-3’); 
ap2 (5’-AAGGTGAAGAGCATCATAACCCT-3’, 5’-
TCACGCCTTTCATAACACATTCC-3’); pparg (5’-
GGAAGACCACTCGCATTCCTT-3’, 5’-GTAATCAGCAACCATTGGGTCA-3’); 
fasn (5’-GGAGGTGGTGATAGCCGGTAT-3’, 5’-
TGGGTAATCCATAGAGCCCAG-3’); glut4 ( 
Srebp-1c (5’-GGAGCCATGGATTGCACATT-3’, 5’-GGCCCGGGAAGTCACTGT-
3’);	  
Scd1 (5’-TTCTTGCGATACACTCTGGTGC-3’, 5’-
CGGGATTGAATGTTCTTGTCGT-3’); adiponectin (5’-
AGAGAAGGGAGAGAAAGGAGATGC-3’, 5’-
TGGTCGTAGGTGAAGAGAACGG-3’); cpt1b (5’-
GCTTTGGCTGCCTGTGTCAGTATGC-3’, ‘5-GCTGCTTCCCCTCACAAGTTCC-
3’) 
 
Flow Cytometry: SVF cells from mice treated with fluorescein-GeRPs were 
incubated for 20 min in blocking buffer containing 1% BSA and Fc block 
(eBioscience) and allowed to block nonspecific binding for 15 min at 4 °C. Cells 
were then counted and incubated for an additional 20 min in the dark at 4 °C with 
fluorophore-conjugated primary antibodies or isotype control antibodies (AbD 
Serotec). Antibodies used in these studies included: F4/80-allophycocyanin 
(APC), CD11b-peridinin chlorophyll protein-Cyano 5.5(PErCP- Cy5.5), Gr-1-
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APC-Cyano (Cy)7, Siglec-f-PE, lymphocyte antigen 6C (Ly6C)-phycoerythrin-
Cyano 7 (PE-Cy7), and CD3-PE-Cy7. Subsequently cells were analyzed by flow 
cytometry in an LSRII cytometer (BD Bioscience). FlowJo software (Treestar) 
was used to identify the different cell populations. A total of 10,000 events were 
recorded. For sorting experiments, SVF cells were run through a FACS Vantage 
(BD Bioscience). Both FITC+ and FITC− populations were collected and RNA 
was harvested for RT-PCR.  
 
ELISA: PECs were treated for 6 h with 1 µg/mL LPS, and TNF-α levels in the 
media were measured using mouse ELISA kits (Pierce) as recommended by the 
vendor. Osteopontin (OPN) levels in the media and serum were measured using 
an ELISA kit (R&D Systems).  
 
Microscopy: Fixed SVF cells from in vivo experiments were incubated with rat 
anti-mouse F4/80 primary antibody (AbD-Serotec) followed by goat anti-rat 
Alexafluor 594 secondary antibody (Invitrogen). Cells were mounted in Prolong 
Gold anti-fade with DAPI (Invitrogen). Cell images were obtained with a 
Solamere CSU10 Spinning Disk confocal system mounted on a Nikon TE2000-
E2 inverted microscope. Images were taken with a multi-immersion 20× objective 
with a numerical aperture (N.A.) 0.75; oil: Working distance (W.D.) = 0.35 mm, or 
a 100× Plan Apo VC objective N.A. 1.4, oil: W.D. = 0.13 mm. For tissues, fixed 
sections were H&E stained. Images were obtained using a Zeiss Axiovert 200 
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inverted microscope equipped with a Zeiss AxioCam HR CCD camera with 1,300 
× 1,030 pixels basic resolution and a Zeiss Plan NeoFluar 20×/0.50 Ph2 (DIC II) 
objective. For crown-like structures, fixed sections were incubated with rat anti-
mouse F4/80 primary antibody (AbD- Serotec) followed by goat anti-rat 
secondary antibody conjugated to horseradish peroxidase (AbD-Serotec). 
Images were obtained with a Solamere CSU10 Spinning Disk confocal system 
mounted on a Nikon TE2000-E2 inverted microscope. Images were taken with a 
40× objective.  
 
Immunoblot Analysis: Tissue extracts were prepared using Triton Lysis Buffer 
[20 mM Tris (pH 7.4), 1% Triton X-100, 10% glycerol, 137 mM NaCl, 2 mM 
EDTA, 25 mM β-glycerophosphate, 1 mM sodium orthovanadate, 1 mM 
phenylmethylsulfonyl fluoride, and 10 µg/mL of aprotinin plus leupeptin]. Protein 
concentration was measured using BCA assay (Thermo Scientific). Extracts (25 
µg of protein) were examined by protein immunoblot analysis by probing with 
antibodies to AKT, pSer473AKT (Cell Signaling), α-Tubulin (Sigma), and α-Actin 
(Sigma). Immunocomplexes were detected by enhanced chemiluminescence.  
Multiplexed ELISA of Protein Phosphorylation: Quantitative analysis of 
pSer473-AKT/AKT was performed using Bioplex kits (Bio- Rad) and a Luminex 
200 machine (Millipore).  
 
Statistics: t-test or one-way or two-way ANOVA analysis and Bonferroni or 
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Tukey posttests using GraphPad Prism 5.0a software determined the statistical 
significance of the differences in the means of experimental groups. The data are 
presented as the means ± SEM.  
 
RESULTS 
Biodistribution of GeRPs in Obese Mice.  
        Previous studies from our lab have demonstrated that GeRPs are 
systemically distributed when injected into lean mice (228, 230). To study the 
localization of i.p.-injected GeRPs in obese mice, we used FITC-labeled GeRPs 
loaded with non-targeting scrambled (SCR) siRNA. Five-wk-old ob/ob mice were 
administered GeRPs by i.p. injection daily for 5 d and various tissues, including 
liver, lung, spleen, pancreas, heart, and kidney and SubQ, mesenteric, perirenal, 
and epididymal ATs were analyzed by microscopy (Figure 3.1A–J). FITC-
GeRPs were only observed in cells within the epididymal AT and not in the other 
organs (Figure 3.1A–F) or other adipose depots (Figure 3.1G–I). Similar results 
were obtained when mice were treated with GeRPs for 10 d. These data 
document that GeRPs injected i.p. are mostly found in cells within the epididymal 
AT in obese ob/ob mice. 
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Figure 3.1 GeRPs injected i.p. localize in epididymal ATMs in obese mice 
 
 
Figure 3.1 GeRPs injected i.p. localize in epididymal ATMs in obese mice  
(A–J) Five-week-old ob/ob mice were i.p. injected once a day for 5 d with 5.6 
mg/kg FITC-labeled GeRPs loaded with 2.1 mg/kg EP and 0.262 mg/kg SCR 
siRNA. On day 6, liver, lung, spleen, pancreas, heart, kidney, and (SubQ AT), 
mesenteric (Mes AT), perirenal (PeriR AT), and epididymal AT (EPI AT) were 
isolated. Tissues were fixed, sectioned, and then stained with H&E. Tissues were 
then analyzed by fluorescent microscopy. Images were obtained using a Zeiss 
Axiovert 200 inverted microscope. (Scale bar: 50 µm.) 
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GeRP Uptake in the Epididymal ATMs in Obese Mice.  
        To study the profile of cells in the epididymal AT that internalize GeRPs, we 
performed fluorescence microscopy and flow cytometry analysis. The ob/ob mice 
were i.p. injected daily for 5 d with FITC-GeRPs. On day 6, epididymal AT 
sections were stained with an antibody against the macrophage marker F4/80 
and analyzed by microscopy. Figure 3.2A shows FITC-GeRPs in F4/80-positive 
cells in a region of the epididymal AT macrophage rich CLS. We next performed 
fluorescence microscopy on cells isolated from the SVF, which contains all cells 
in the AT that do not float upon centrifugation, unlike lipid-laden adipocytes 
(Figure 3.2B). SVF cells were isolated from the AT and stained with the F4/80 
antibody (red) and the nuclear stain, DAPI (blue) (Figure 3.2B). Images in 
Figure 3.2B, Left show cells containing FITC-GeRPs only in GeRP-treated mice. 
Analyses at higher magnification (Figure 3.2B, Right) show F4/80-positive cells 
containing multiple FITC-GeRPs. Flow cytometry analysis confirmed the 
presence of FITC-GeRPs in F4/80-positive cells in the epididymal AT (Figure 
3.2C, Upper Right). Importantly, an FITC signal was detected in phagocytic 
cells, including F4/80-positive macrophages and F4/80 intermediate and negative 
monocytes and neutrophils (Figure 3.2C, Lower Right). Similar results were 
obtained when mice were treated with GeRPs for 10 d. These results show that 
GeRPs injected i.p. are specifically delivered to phagocytes in the epididymal AT 
of obese ob/ob mice. 
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Figure 3.2 – ATMs in obese mice phagocytose GeRPs 
 
 
Figure 3.2 ATMs in obese mice phagocytose GeRPs  
(A) Five-week-old ob/ob mice were i.p. injected once a day for 5 d with 5.6 mg/kg 
FITC-labeled GeRPs loaded with 2.1 mg/kg EP and 0.262 mg/kg SCR siRNA. 
On day 6, epididymal AT was isolated, fixed, sectioned, and stained with F4/80 
antibody. Tissues were also counterstained with hematoxylin. Tissues were then 
analyzed by fluorescent microscopy. Spinning disk confocal microscopy showing 
crown-like structures composed of macrophages (dark brown) containing FITC 
GeRPs (green). (Scale bar: 20 µm.) (B) Confocal microscopy showing F4/80 
(red) and GeRPs (green) present in SVF cells 24 h after treatment. Nuclei were 
stained with DAPI (blue). (Scale bar: Left, 50 µm; Right, 10 µm.) (C) FACS 
analysis showing SVF cells isolated from mice treated with FITC-labeled GeRPs 
(FITC-GeRPs) and stained with F4/80 antibody. APC: allophycocyanin. 
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Gene Silencing in Primary Macrophages.  
We first measured the expression of OPN in epididymal and SubQ ATMs of 7-
wk-old obese ob/ob mice and found strong increases of expression of these 
genes in epididymal ATMs of ob/ob mice compared with their lean WT littermates 
(Figure 3.3A). The increase in OPN expression in epididymal ATMs confirmed 
that the increase in macrophage content occurs mainly in the VAT in the obese 
state. Primary peritoneal macrophages were used to screen for potent siRNAs 
against OPN, and two were chosen for (Figure 3.3B). Both siRNA sequences 
potently silenced the expression of OPN. Furthermore, secretion of OPN was 
significantly silenced by the targeting siRNAs compared with SCR or untreated 
cells (Figure 3.3C). The data reveal that OPN could be silenced in primary 
macrophages in vitro both at the mRNA and protein levels. 
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Figure 3.3 – Silencing OPN in primary macrophages in vitro. 
 
 
 
 
Figure 3.3 Silencing OPN in primary macrophages in vitro  
(A) Expression of OPN measured by RT-PCR in isolated macrophages from 
epididymal and SubQ AT of 7-wk-old genetically obese ob/ob mice. 
Macrophages were isolated using CD11b antibody bound to magnetic beads; n = 
4. Statistical significance was determined by t test. ***P < 0.001; *P < 0.05. 
Results are means expressed in fold change (F.C.) ± SEM. (B) 1 x 106 peritoneal 
macrophages were treated with particles made with a mixture of160 pmoles 
siRNA and 3 nmol EP. Forty-eight hours after the treatment, mRNA levels were 
measured by RT-PCR. (C) OPN protein basal levels in media measured by 
ELISA; n = 3 with three technical replicates for each experiment. Statistical 
significance was determined by ANOVA and Tukey post test. ***P < 0.001. 
Results are mean ± SEM. 
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Gene Silencing in Epididymal ATMs in Obese Mice.  
        To test the ability of GeRPs to deliver functional siRNA and silence OPN in 
vivo, 5-wk-old ob/ob mice were injected daily for 5 d with GeRPs loaded with 
SCR or OPN siRNA, validated as shown in Figure 3.3.The day after the last 
injection, OPN expression was measured in epididymal AT (Figure 3.4A). OPN 
expression was significantly knocked down by 70% in the epididymal AT of ob/ob 
mice treated with OPN- GeRPs compared with SCR-GeRPs (Figure 3.4A). To 
confirm the specificity of the siRNA-mediated knockdown, the expression of 
several other macrophage and immune cell factors was measured, including 
CD11b, CD11c, F4/80, CD68, IL-1β, IL-6, IL-10, IL-4, CC-motif chemokine 
receptor-2 (CCR2), monocyte chemoattractant protein 1 (MCP-1), and adipocyte 
protein 2 (aP2). Expression of these markers was unchanged in mice treated 
with OPN-GeRPs compared with SCR-GeRPs (Figure 3.4B). This result 
confirmed the specificity of siRNA-mediated knockdown and suggested that 
silencing OPN expression had no effect on global AT inflammation during the 
experiment.  
        Consistent with the biodistribution studies showing GeRPs were present 
only in phagocytic cells of epididymal AT and not in liver, no depletion of the 
target gene products was observed in liver of treated mice (Figure 3.4C). Mice 
treated with OPN-GeRPs had a significant 81% decrease of OPN secretion in 
SVF isolated from epididymal AT compared with mice treated with SCR-GeRPs 
(Figure 3.4D). FACS was performed to analyze the knockdown of OPN in ATMs 
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containing FITC-labeled GeRPs (Fig. 4J). OPN expression was significantly 
silenced in sorted F4/80+/FITC+ ATMs in mice treated with OPN-GeRPs, 
compared with SCR-GeRPs (Figure 3.4E). Taken together, these data reveal 
that i.p.-injected GeRPs can specifically silence genes in epididymal ATMs in 
vivo without affecting gene expression in macrophages in other major organs 
such as liver. 
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Figure 3.4 – Specific silencing of OPN in ATMs of epididymal AT 	  
	   	   	   	  	   	  
 
 
 
Figure 3.4 Specific silencing of OPN in ATMs of epididymal AT  
Expression of OPN in (A) epididymal AT and (C) liver from mice treated for 5 d 
with SCR- or OPN-GeRPs. (B) Expression of inflammatory genes in AT of ob/ob 
mice treated with SCR- or OPN-GeRPs; n = 28. Statistical significance was 
determined by t test. ***P < 0.001; *P < 0.05. Results are means in F.C. ± SEM. 
(D) OPN protein levels in epididymal SVF media of mice treated with SCR- or 
OPN-GeRPs; n = 10. Statistical significance was determined by t-test. **P < 
0.01; *P < 0.05. (J) Mice were treated with FITC-labeled SCR- or OPN-GeRPs 
for 5 d. F4/80+ cells containing GeRPs were sorted by FACS and mRNA levels 
were measured by RT-PCR; n = 3 groups of three mice pooled together. 
Statistical significance was determined by t-test. ***P < 0.001. 
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Silencing Inflammatory Genes in Epididymal ATMs Affects Whole-Body 
Metabolism in ob/ob Mice.  
        To test the effect of GeRP-mediated gene silencing in epididymal ATMs on 
whole-body metabolism, glucose tolerance tests were performed in ob/ob mice 
treated with OPN-GeRPs or SCR-GeRPs (Figure 3.5A). OPN silencing in 
epididymal ATMs improved glucose tolerance in obese mice (Figure 3.5A). Area 
under the glucose tolerance test curve showed that mice treated with OPN-
GeRPs were significantly more glucose tolerant compared with mice treated with 
PBS or SCR-GeRPs (Figure 3.5B). Importantly, this occurred without affecting 
OPN expression in other tissues or protein levels in serum, where OPN levels 
unchanged (Figure 3.4C and Figure 3.5C). The effect of OPN silencing on 
glucose tolerance was independent of an effect on weight gain during treatments 
(Figure 3.5D). Taken together, these results suggest that decreasing production 
of these cytokines specifically in epididymal ATMs has a beneficial effect on 
whole-body metabolism.  
        To study the effect of OPN silencing in ATMs on systemic insulin sensitivity, 
we performed insulin tolerance tests in mice treated with PBS-, SCR-, or OPN-
GeRPs (Figure 3.5E and F). Mice treated with OPN-GeRPs had a significant 
improvement in insulin response compared with mice treated with PBS or SCR-
GeRPs (Figure 3.5E and F). Measurement of fasting insulin levels showed that 
mice showed no differences between the groups (Figure 3.5G). These results 
suggested that OPN silencing in ATMs increases systemic insulin sensitivity. 
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Figure 3.5 – OPN silencing in ATMs in obese mice regulates whole-body 
metabolism 
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Figure 3.5 OPN silencing in ATMs in obese mice regulates whole-body 
metabolism  
(A) Five-week-old ob/ob mice were treated as described in Figure 4.4. Twenty-
four hours after the last injection, glucose tolerance tests (GTT) were performed 
on mice that were fasted for 16 h. Mice were treated with SCR-GeRPs or OPN-
GeRPs. (B) Area under the curve (AUC) of GTT graph; n = 10–18. Statistical 
significance was determined by ANOVA and Tukey posttest. *P < 0.05. Results 
are mean ± SEM. (C) Serum OPN levels in ob/ob mice treated for 5 d with PBS 
or SCR- or OPN-GeRPs; n = 10–15. (D) Total body weight gain in ob/ob mice 
treated for 5 d with PBS or SCR- or OPN-GeRPs; n = 10–15 (E) Insulin tolerance 
tests (ITT) were performed on day 6 in ob/ob mice treated with PBS or SCR- or 
OPN-GeRPs by injecting 1 U/kg of insulin. (F) AUC of ITT graph; n = 15. 
Statistical significance was determined by ANOVA and Tukey posttest. *P < 0.05. 
Results are mean ± SEM. (G) Serum insulin levels during GTT in mice treated 
with PBS or SCR- or OPN-GeRPs; n = 10. 
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ATM-derived OPN affects insulin signaling and adipocyte biology 
 
        The role of OPN in the development of insulin resistance has been 
attributed to its role in attracting macrophages in the epididymal AT (21, 22). To 
test this, macrophage content was analyzed in the epididymal AT of mice treated 
with OPN-GeRPs compared with SCR-GeRPs (Figure 3.6A). Epididymal ATM 
content was unchanged in OPN-GeRP–treated mice compared with mice treated 
with SCR-GeRPs (Figure 3.6A). This suggests that OPN silencing in epididymal 
ATMs prevents obesity-induced insulin resistance independently of macrophage 
recruitment. Analysis of circulating lipids showed that OPN silencing in 
epididymal AT had no effect on lipolysis (Figure 3.6B and C). Therefore, we also 
performed biochemical studies to investigate insulin-stimulated AKT activation in 
mice treated with PBS, SCR-GeRPs, or OPN-GeRPs (Figure 3.6D). Obesity 
suppressed insulin-stimulated AKT activation in liver, AT, and skeletal muscle of 
mice treated with PBS or SCR-GeRPs but not in AT of mice treated with OPN-
GeRPs (Figure 3.6D). Together, these data demonstrate that silencing OPN in 
ATMs improves insulin sensitivity in AT. Furthermore, OPN levels were 
specifically decreased in epididymal AT and not in other tissues or serum (Figure 
3.4), suggesting that it may play a paracrine role in the AT. To determine whether 
OPN knockdown affected adipocyte function, we measured the expression of a 
number of adipocyte genes in adipocytes from mice treated with SCR- or OPN-
GeRPs. By RT-PCR two genes showed a significant increase in gene 
expression: PPARγ and FASN. As discussed in Chapter 1, these genes are key 
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regulators of adipogenesis and lipogenesis respectively. This data taken together 
suggests ATM-OPN negatively affects adipocyte function and insulin signaling in 
obese mice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  
99	  
Figure 3.6 – OPN knockdown in ATMs affects adipocyte biology and insulin 
signaling 
 
	  
 
	  
 
.
D 
.
. . 
0 
0.5 
1 
1.5 
2 
2.5 
SCR OPN 
PPARG 
0 
1 
2 
3 
4 
5 
6 
7 
SCR OPN 
FASN 
0 
0.5 
1 
1.5 
2 
2.5 
SCR OPN 
GLUT4 
* * 
E 
0 
0.5 
1 
1.5 
2 
2.5 
SCR	   OPN	  
SCD1 
0 
0.5 
1 
1.5 
2 
2.5 
SCR OPN 
Adiponectin 
0 
0.5 
1 
1.5 
2 
2.5 
SCR OPN 
CPT1b 
	  
100	  
 
Figure 3.6 OPN Knockdown in ATMs affects adipocyte biology and insulin 
signaling  
(A) Macrophage content in the epididymal SVF of mice treated with PBS 
or SCR- or OPN-GeRPs measured by flow cytometry. (B) Fasted FFA and (C) 
TG serum levels in ob/ob mice treated with PBS or SCR- or OPN-GeRPs; n = 5–
10. (D) PBS or SCR- or OPN-GeRPs treated mice were also fasted for 4 h and 
then treated by i.p. injection with 1 U/kg of insulin (15 min). Western blotting and 
multiplexed ELISA were used to detect AKT and activated (pSer473) AKT in 
epididymal AT (EPI AT), gastrocnemius muscle and liver; n = 5–6. Statistical 
significance was determined by ANOVA and Tukey posttest. ***P < 0.001; *P < 
0.05. Results are mean ± SEM. (E) Expression of adipocyte genes in isolated 
adipocytes of ob/ob mice treated with SCR- or OPN-GeRPs; n = 14-15. 
Statistical significance was determined by t test. *P < 0.05. 
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Osteopontin deficient mice are not protected from diet induced obesity and 
systemic glucose metabolism. 
        To test whether the effects of GeRP-mediated OPN KD in obese mice could 
be reproduced in OPN-deficient mice, I obtained global OPN KO mice from 
Jackson Labs. Heterozygous mice were bred together to generate KO animals 
and WT controls to be used in subsequent experiments. Opn-/- and WT mice 
were placed on either the 45%HFD or the 60%HFD for 19 weeks and 10 weeks 
respectively (Figure 3.7A and B). There was no significant difference in weight 
gain between KO and WT groups on either the chow diet or the two different 
HFDs, although there as a trend toward less weight gain in KO on the 45%HFD 
(Figure 3.7A) These mice were then subjected to glucose tolerance tests to 
determine whether OPN deficiency had any effect on systemic glucose 
metabolism. OPN KO animals did not show any improvement in glucose 
tolerance when placed on either of the HFDs (Figure 3.7C and D), and 
interestingly there was a trend toward worse glucose tolerance in the KO animals 
on the 60%HFD (Figure 3.7D). In order to confirm the depletion of OPN in the 
KO mice blood was collected from all animals at the time of dissection, and an 
OPN ELISA was performed on the serum using a commercially available kit and 
per the manufacturer’s instruction. WT controls showed a circulating 
concentration in the range of 230-246ng/mL while in the KO mice, OPN could not 
be detected (Figure 3.7E).  
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Figure 3.7 – OPN KO mice develop diet induced obesity and glucose 
intolerance 
 
Figure 3.7 OPN KO mice develop diet-induced obesity and glucose 
intolerance  
(A) Eight-week-old opn-/- and WT controls were placed on either a chow diet or a 
diet of 45%kcal fat for 19 wks. (B) Ten-week-old opn-/- and WT controls were 
placed on either a chow diet or a diet of 60%kcal fat for 10 wks. (C) GTTs were 
performed on mice that were fasted for 16 h; n=5 (D) GTTs were performed on 
mice that were fasted for 16 h; n=4-10 (E) OPN ELISA was performed on serum 
samples from opn-/- and WT controls on either chow diet or a diet of 60%kcal fat 
for 10 wks; n=4-10. Results are mean ± SEM. 
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DISCUSSION 
        The major findings reported here include the development of a powerful 
RNAi-based method to selectively silence genes in epididymal ATMs in obese 
mice while leaving such cells unperturbed in other tissues (Figures 3.1 and 3.2). 
This selective biodistribution profile of i.p.-injected GeRPs in obese mice is in 
keeping with the known high accumulation of macrophages in visceral AT 
compared with other adipose depots and metabolic tissues in obese rodents and 
humans (254-256). In previous studies using lean healthy animals, i.p.-injected 
GeRPs were internalized by macrophages that could be detected throughout the 
body (228, 230). In contrast, using obese insulin-resistant animals, we detected 
GeRPs mostly in the epididymal ATMs following i.p. injection. One explanation 
for the different patterns of GeRP distribution observed in lean versus obese 
mice could be the increase in AT chemoattractants in obesity. Adipocytes 
produce a wide range of such factors, such as MCP-1, which may recruit 
monocytes expressing its receptor CCR2 to adipose tissue in obese mice (257, 
258). 
        Although multiple siRNA delivery systems have been recently described in 
the literature (259, 260), none has been used in an obese, insulin-resistant 
animal model. A previous study described delivery of lipidoid nanoparticles 
carrying siRNA to immune cells, including lymphocytes, in spleen, blood, and 
bone marrow following i.v. injection in lean mice (261). In contrast, we show here 
that GeRPs are only found in phagocytes, which could represent a major clinical 
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advantage. This important feature of the GeRPs is conferred by their size (2–4 
µm) and the β-1,3-D-glucan that is specifically recognized by receptors 
expressed by phagocytic cells (234). 
        Decreasing inflammation in obese rodents often results in improvement of 
insulin sensitivity (102). However, blocking cytokines by injection of antibodies or 
antagonists has yielded mixed results in alleviating insulin resistance in humans 
(205, 262-265). An explanation for the frequently observed absence of effects of 
these drugs on insulin resistance in obese subjects may be their low penetrance 
in AT in which the endogenous cytokines act in a paracrine fashion (266). 
However, no study has actually shown a direct role of macrophages in the AT in 
the regulation of systemic metabolism because experimental anti-inflammatory 
gene knockouts and other procedures are not restricted to AT, but in general act 
on immune cells within all tissues. Macrophages in particular are present in all 
tissues, and cytokines are highly expressed by various immune and nonimmune 
cells (Chapter 1). Therefore, the physiological role of ATMs has been a key 
unanswered question in the field, and is particularly important considering the 
variable results obtained with cytokine blockers in human subjects. 
        The specificity of GeRPs in targeting epididymal ATMs when administered 
i.p. permitted us to address this critical question (Figures 3.4 and 3.5). The 
motivation for targeting OPN in epididymal ATMs in our studies was based on 
three major points: (i) OPN−/− mice are protected from obesity-induced insulin 
resistance (208); (ii) the expression OPN is high in AT from obese mice (Figure 
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3.3) (208, 212); and (iii) anti-OPN neutralizing antibody reverses obesity-induced 
insulin resistance in rodents (212). Based on these considerations, GeRPs were 
loaded with siRNAs to silence OPN in genetically obese ob/ob mice. Although 
previous work by our laboratory and others demonstrated that GeRPs can 
mediate potent gene silencing in peritoneal macrophages in lean mice (228-230), 
here we found specific gene knockdown within epididymal ATMs in obese mice. 
        Importantly, GeRP-mediated OPN silencing in epididymal ATMs improved 
the glucose tolerance of ob/ob mice (Figure 3.5). Silencing OPN had no effect on 
the expression of CD11b, CD11c, F4/80, CD68, IL-1β, IL-6, IL-10, IL-4, CCR2, 
MCP-1, or aP2 in AT, suggesting that none of these inflammatory mediators is 
downstream of OPN in this context. Thus, the selective depletion of OPN in the 
absence of changes in these other factors was sufficient to improve glucose 
tolerance (Figure 3.4). Notably, OPN silencing in ATMs specifically increased 
PPARγ and FASN expression, as well as insulin-stimulated AKT activation in AT.  
This suggests a paracrine role of macrophage OPN in improving insulin signaling 
and adipocyte function (Figure 3.6). Thus, this study shows a direct link between 
epididymal ATM-derived cytokines and insulin resistance. 
        Previous studies have demonstrated that OPN-deficient mice are protected 
from the complications associated with DIO and T2DM such as insulin 
resistance, hyperglycemia and hepatic steatosis (208, 213). We therefore sought 
to reproduce this protective effect as well as confirm the beneficial effects of our 
OPN-GeRPs by challenging OPN KO mice with two different high fat diets. 
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However, we were surprisingly unable to show any benefits to global depletion of 
OPN in obese mice (Figure 3.7). A possible reason for this could be the 
differences in housing facilities between previous studies and ours. In recent 
years the hypothesis that gut microbiota could play an important and 
unrecognized role in whole body metabolism has been generating a lot of 
interest. Differences in the microbiome could determine the metabolic response 
in humans and rodents, regardless or in addition to genetic and environmental 
factors (267). Therefore the microbes unique to our facility could have played a 
role in the data we obtained from our KO animals, which is inconsistent with that 
in other previously published studies. 
        This study illustrates the crucial role of macrophage local environment and 
emphasizes the importance of studying macrophage function within a specific 
tissue. Although additional work is needed to define the molecular mechanisms 
by which these macrophage proteins regulate whole-body metabolism, the GeRP 
siRNA delivery system provides a unique tool for such studies. 
 
 
 
 
 
 
	  
107	  
Chapter IV: Lipid storage by adipose tissue macrophages regulates 
systemic glucose tolerance 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter is derived from an article by the same name published in the 
Journal of Lipid Research. 
Aouadi, M., Vangala, P., Yawe, J. C., Tencerova, M., Nicoloro, S. M., Cohen, J. 
L., Shen Y and Czech, M. P. (2014) Lipid storage by adipose tissue 
macrophages regulates systemic glucose tolerance. Am J Physiol Endocrinol 
Metab 307, E374-383 
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SUMMARY 
        Proinflammatory pathways in ATMs can impair glucose tolerance in obesity, 
but ATMs may also be beneficial as repositories for excess lipid that adipocytes 
are unable to store. To test this hypothesis, we selectively targeted visceral 
ATMs in obese mice with siRNA against lipoprotein lipase (LPL), leaving 
macrophages within other organs unaffected. Selective silencing of ATM LPL 
decreased foam cell formation in visceral adipose tissue of obese mice, 
consistent with a reduced supply of fatty acids from VLDL hydrolysis. 
Unexpectedly, silencing LPL also decreased the expression of genes involved in 
fatty acid uptake (CD36) and esterification in ATMs. This deficit in fatty acid 
uptake capacity was associated with increased circulating serum free fatty acids.  
Additionally, obese mice with LPL-depleted ATMs exhibited higher hepatic 
glucose production from pyruvate and glucose intolerance. Silencing 
Taken together, the data indicate that LPL secreted by ATMs enhances their 
ability to sequester excess lipid in obese mice, promoting systemic glucose 
tolerance. 
 
INTRODUCTION 
        The inability to appropriately expand AT in human obesity may lead to 
ectopic lipid deposition in liver and skeletal muscle and may be an underlying 
cause of insulin resistance (70, 250, 251). Accumulation of immune cells 
including macrophages in the visceral AT of obese mice and humans creates a 
	  
110	  
chronic inflammatory state that correlates with insulin resistance (32, 110, 252). 
These AT macrophages (ATMs) secrete cytokines and other factors that may 
impair adipocyte capacity to store lipids (32, 110, 252), promoting the ectopic 
deposition of lipid in nonadipose tissues. However, some data indicate a 
beneficial role of ATMs, for example, in increasing adipose lipid storage (268). 
ATMs are also required for maintenance of AT homeostasis by regulating 
angiogenesis, extracellular matrix remodeling, and clearance of dead cells in AT 
(132, 269-272). It is therefore likely that macrophages exert multiple, even 
opposing effects on adipocytes, depending upon physiological conditions. 
        To determine whether ATMs contribute to lipid storage and glucose 
tolerance, we silenced the expression of lipoprotein lipase (LPL) by ATMs. LPL is 
released by cells within AT and is translocated to the lumen of adipose 
capillaries, where it binds the glycosylphosphatidylinositol-anchored high-density 
lipoprotein-binding protein-1 (GPIHBP1) (273, 274). LPL is known to control 
localized VLDL triglyceride (TG) hydrolysis and uptake of fatty acids into the 
tissue (273, 274). The contribution of macrophage-LPL in this function is 
suggested by experiments showing that depletion of macrophage LPL is effective 
in reducing lipid-laden foam cell formation in arteries of LDL receptor-null mice 
(275). Here, we employed GeRPs to silence gene expression of LPL specifically 
in ATMs in obese mice without perturbing macrophages in other tissues, 
including liver. Such selective silencing of LPL in ATMs of obese mice decreased 
foam cell formation in AT and caused a marked impairment in glucose tolerance, 
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indicating that ATMs contribute to beneficial lipid storage within AT. 
 
MATERIALS AND METHODS 
All procedures involving animals were approved by the Institutional 
Animal Care and Use Committee at the University of Massachusetts 
Medical School. 
 
Preparation of GeRPs: As described previously (Chapter 3). 
 
Peritoneal macrophage preparation: As described previously (Chapter 3), 
using Eight-week-old C57BL6/J male mice.  
 
Gene silencing by siRNA/EP particles in vitro in cell culture: As described 
previously (Chapter 3). 
 
GeRP administration and tissue isolation: Eight-week-old 
C57BL6/J or 5-wk-old ob/ob male mice were injected once a day for 
five days with 5.6 mg/kg GeRPs ip loaded with 2.1 mg/kg EP and 
0.262 mg/kg siRNA. Further analyses were performed 24 h after the 
last injection. siRNA sequences used are as follows: Scrambled (SCR) 5’-
CAGUCGCGUUUGCGACUGGUU-3’; anti-LPL (5’-
UCUCAGACAUCGAAAGCAAUU-3’) 
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Isolation of adipocytes, stromal vascular fraction (SVF) cells, and 
ATMs: Epididymal fat pads were mechanically dissociated using the 
GentleMACS Dissociator (Miltenyi Biotec) and collagenase was digested at 37°C 
for 45 min in Hank’s buffered saline solution (HBSS; GIBCO, Life technologies), 
containing 2% bovine serum albumin (American Bioanalytical) and 2 mg/ml 
collagenase (Sigma-Aldrich). Samples were then filtered through 100µm 
diameter pore nylon mesh and centrifuged. The adipocyte layer was collected 
and washed for further analysis. The pelleted cells were collected as the SVF. 
The SVF cells were then treated with red blood cell lysis buffer and washed in 
PBS and plated or directly harvested for further analysis. For ATM isolation, the 
SVF pellet was resuspended in 1 ml of selection buffer (PBS, 2 mmol/l EDTA, 
and 0.5% BSA), and the CD11b-positive cells were selected using CD11b 
microbeads (Miltenyi Biotec), according to the manufacturer’s instructions. 
 
Isolation of RNA and real-time PCR: As described previously (Chapter 2). 
Primer sequences used were as follows: 36B4 (5’TCCAGGCTTTGGGCATCA-3’, 
5’-CTTTATCAGCTGCACATCACTCAGA-3’); lpl (5’-TCTGTACGGCACAGTGG-
3’, 5’-CCTCTCGATGACGAAGC-3’); cd36 (5’-ATGGGCTGTGATCGGAACTG-3’, 
5’-TTTGCCACGTCATCTGGGTTT-3’); vldlr (5’-CTCCCAGTTTCAGTGCACAA-
3’, 5’-ATCAGAACCGTCTTCGCAAT-3’); elovl6 (5’-TCAGCAAAGCAGCCGAAC-
3’, 5’-AGCGACCATGTCTTTGTAGGAG-3’);  
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ap2 (5’-AAGGTGAAGAGCATCATAACCCT-3’, 5’-
TCACGCCTTTCATAACACATTCC-3’); pparg (5’-
GGAAGACCACTCGCATTCCTT-3’, 5’-GTAATCAGCAACCATTGGGTCA-3’); 
fasn (5’-GGAGGTGGTGATAGCCGGTAT-3’, 5’-
TGGGTAATCCATAGAGCCCAG-3’); glut4 (5’-GTGACTGGAACACTGGTCCTA-
3’,  5’-CCAGCCACGTTGCATTGTAG-3’); Scd1 (5’-
TTCTTGCGATACACTCTGGTGC-3’, 5’-CGGGATTGAATGTTCTTGTCGT-3’); 
dgat2 (5’-GCGCTACTTCCGAGACTACTT-3’, 5’-GGGCCTTATGCCAGGAAACT-
3’) 
 
Western blot: As described previously (Chapter 3). 
 
Flow cytometry: SVF cells from mice treated with FITC-GeRPs were incubated 
for 20 min in blocking buffer containing 1% BSA and Fc block (eBioscience) for 
15 min at 4°C to block nonspecific binding. Cells were then counted and 
incubated for an additional 20 min in the dark at 4°C with fluorophore-conjugated 
primary antibodies or isotype control antibodies (AbD Serotec). Antibodies used 
in these studies included F4/80-APC (AbD Serotec), CD11b-PerCP-Cy5.5 (BD 
bioscience), and Bodipy-FITC (Invitrogen). Subsequently, cells were analyzed by 
flow cytometry in an LSRII cytometer (BD Bioscience). FlowJo software 
(Treestar) was used to identify the different cell populations; 100,000 events 
were recorded. For sorting experiments, SVF cells were run through a FACS 
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Vantage (BD Bioscience). Both FITC_ and FITC_ populations were collected, 
and RNA was harvested for RT-PCR. 
 
Microscopy: For SVF, fixed cells were incubated with rat anti-mouse 
F4/80 primary antibody (AbD-Serotec) followed by goat anti-rat Alexa fluor 594 
secondary antibody (Invitrogen). Cells were mounted in Prolong Gold anti-fade 
with DAPI (Invitrogen). Cell images were obtained with a Solamere CSU10 
Spinning Disk confocal system mounted on a Nikon TE2000-E2 inverted 
microscope. For tissues, fixed sections were stained with hematoxylin and eosin 
(H&E). Images were obtained using a Zeiss Axiovert 200 inverted microscope 
equipped with a Zeiss AxioCam HR CCD camera with 1,300 x 1,030 pixels basic 
resolution and a Zeiss Plan NeoFluar x20/0.50 Ph2 (DIC II) objective. 
 
Transmission electron microscopy: Samples were processed and analyzed at 
the University of Massachusetts Medical School Electron Microscopy Core 
Facility according to standard procedures. Briefly, pieces of whole adipose tissue 
were fixed in 2.5% gluteraldehyde in 0.1 M sodium cacodylate buffer and left 
overnight at 4°C. The samples were then rinsed twice in the same fixation buffer 
and postfixed with 1% osmium tetroxide for 1 h at room temperature. Samples 
were then washed twice with DH2O for 5 min and then dehydrated through a 
graded ethanol series of 20% increments, before two changes in 100% ethanol. 
Samples were then infiltrated first with two changes of 100% propylene oxide and 
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then with a 50%/50% propylene oxide-SPI-Pon 812 resin mixture. The following 
day, three changes of fresh 100% SPI-Pon 812 resin were done before the 
samples were polymerized at 68°C in plastic capsules. The samples were then 
thin-sectioned, and the sections were placed on copper support grids and 
contrasted with lead citrate and uranyl acetate. Sections were examined using 
the FEI Tecani 12 BT with 80 Kv accelerating voltage, and images were captured 
using a Gatan TEM CCD camera. 
 
TG, LDL/VLDL, HDL-cholesterol, and FFA measurements: TG, 
LDL/VLDL, HDL-cholesterol, and FFA concentrations in serum and liver 
homogenate were measured using commercial kits according to manufacturer’s 
protocol (Cayman Chemical). 
 
Glucose and pyruvate tolerance tests: Pyruvate and glucose tolerance tests 
were performed on ob/ob animals 5 days after GeRP treatment. Pyruvate (1 
g/kg) and glucose (1 g/kg) were administered by intraperitoneal injection. Blood 
samples were withdrawn from the tail vein at the indicated time, and glycemia 
was determined using glucometers (Bayer-Breeze 2 and Abbott Alphatrak). 
 
Statistics: Student’s t-test, one-way or two-way ANOVA and Bonferroni, or 
Tukey’s posttests using GraphPad Prism 5.0a software determined the statistical 
significance of the differences in the means of experimental groups. The data are 
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presented as means + SE. 
RESULTS 
Lipid uptake by ATMs increases with obesity  
        To determine the role of ATM lipid handling in systemic metabolism, we first 
measured the effect of obesity on formation of lipid-laden macrophages in the 
AT. Flow cytometry was performed on the SVF of 6-wk-old obese ob/ob mice 
and wild-type (WT) lean controls, using antibodies against the macrophage 
markers F4/80 and CD11b and the lipid stain bodipy (Figure 4.1). Consistent 
with previous studies (134), the percentage of lipid-laden macrophages (defined 
as bodipy+F4/80+CD11b+) was significantly increased in the VAT of ob/ob 
compared with WT mice (Figure 4.1A and B). To confirm the presence of foam 
cells in AT, fluorescence and transmission electron microscopy (TEM) were 
performed on epididymal SVF of ob/ob mice (Figure 4.1C and D). Figure 4.1C 
shows a representative macrophage (F4/80, red) containing lipid droplets 
(bodipy, green). The TEM image presented shows a macrophage with 
characteristics described in previous studies (110, 246), with lipid droplets 
(arrows) confirming the presence of lipid-laden macrophages in the VAT of ob/ob 
mice (Figure 4.1D).  
        SVF contains multiple cell types; therefore to determine specific gene 
expression changes in macrophages, we isolated ATMs by using CD11b 
magnetic bead pull-down from WT and ob/ob AT. We then measured the 
expression of LPL as well as other genes involved in lipid metabolism, including 
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FASN, CD36, VLDL receptor (VLDLr), PPARγ, SCD1, and fatty acid-binding 
protein-4 (fabp4/aP2) (Figure 4.1E). Only the expression of LPL was significantly 
increased in epididymal ATMs of ob/ob mice compared with their lean WT 
littermates (Figure 4.1E). Together, the data confirms that obesity induces foam 
cell formation in VAT, and the accumulation of lipid is occurs via lipid uptake 
rather than de novo lipogenesis.   
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Figure 4.1 - Formation of lipid-laden macrophages in epididymal adipose 
tissue (AT) of obese mice. 
 
 
Figure 4.1 Formation of lipid-laden macrophages in epididymal adipose 
tissue of obese mice  
Stromal vascular fraction (SVF) from epididymal AT (VAT) of WT and ob/ob mice 
was isolated and analyzed by flow cytometry. (A) Representative flow cytometry 
dot plots and mean fluorescence intensity (MFI) of AT macrophages (ATMs) 
stained with bodipy. (B) Percentage of macrophages stained with bodipy; n = 10. 
(C) microscopy of SVF isolated from ob/ob VAT stained with antibodies against 
F4/80 (red) and bodipy (green); x20 (scale bar, 50 µm). (D) TEM of whole VAT of 
ob/ob mice; A, adipocyte; M, macrophage; arrows, lipid droplet; scale bar, 2 µm. 
(E) Gene expression measured by RT-PCR in macrophages isolated using 
CD11b antibody bound to magnetic beads; n = 5. All graphs are expressed as 
means + SE. Statistical significance was determined by Student’s t-test. ***P < 
0.001, **P < 0.01, *P < 0.05. 
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GeRP-mediated LPL silencing decreases lipid uptake by ATMs  
        To test the hypothesis that LPL is required for lipid uptake by macrophages 
in AT, LPL was selectively depleted in ATMs of obese mice by intraperitoneal 
injections with GeRPs loaded with SCR or LPL siRNA (see protocol outline in 
Figure 4.2A). As previously described (Chapter 3), silencing was specific to 
visceral phagocytes, as no depletion of the target gene products was observed in 
livers of GeRP-treated mice (Figure 4.2B). Other studies we have performed 
showed no gene silencing with this technique in macrophages present in other 
tissues of the obese mice, including lung, pancreas, spleen, and muscle 
(Chapter 3). LPL protein levels in SVF isolated from epididymal AT of mice 
treated with LPL-GeRPs were also significantly reduced compared with mice 
treated with SCR-GeRPs (Figure 4.2C). Importantly, flow cytometry showed that 
silencing LPL in ATMs significantly decreased lipid accumulation in VAT 
macrophages (Figure 4.2D). Careful analysis of epididymal AT sections by TEM 
showed lipid droplets in macrophages containing GeRPs within AT. Treatment 
with LPL-GeRPs reduced the presence of these lipid droplets in ATM (Figure 
4.2E). These results suggested that ATM LPL contributes to obesity-induced lipid 
uptake by macrophages in VAT. 
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Figure 4.2 - GeRP-mediated ATM LPL silencing decreases formation of 
lipid-laden macrophages in VAT of obese mice. 
     
                   
 
 
Figure 4.2 GeRP-mediated ATM LPL silencing decreases formation of lipid-
laden macrophages in VAT of obese mice  
(A) Outline of GeRP treatment given to mice. (B) mRNA expression of LPL in 
VAT and liver from mice treated with SCR- or LPL-GeRPs; n =14–15. (C) 
Representative LPL Western blot and densitometry using epididymal SVF lysates 
from mice treated with SCR- or LPL -GeRPs. Actin was used as a loading 
control. Statistical significance was determined by Student’s t-test. **P <0.01, 
*P <0.05. (D) Percentage of macrophages expressing bodipy; n = 10. All graphs 
A 
E 
	  B 
C B 
D 
	  
121	  
are expressed as means + SE. Statistical significance was determined by 
Student’s t-test. ***P < 0.001, **P < 0.01, *P < 0.05. (E) TEM of whole VAT from 
ob/ob mice treated with SCR- or LPL-GeRPs; A, adipocyte; arrows, GeRPs. 
Scale bar, 5 µm. 
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LPL silencing in ATMs increases serum FFA levels  
         Treatment of ob/ob mice with LPL-GeRPs had no impact on serum TG 
levels, LDL/VLDL-cholesterol, and HDL-cholesterol (Figure 4.3A and B), 
consistent with a recent study showing that LPL depletion in the myeloid lineage 
has no effect on circulating TG and cholesterol levels (276). Therefore, steady-
state circulating TG levels could be maintained in mice treated with LPL-GeRPs 
compared with SCR-GeRPs by the normal expression of LPL in other tissues. 
Although LPL silencing had no impact on serum TG and cholesterol levels, 
serum FFA levels were significantly increased following ATM LPL silencing 
(Figure 4.3C). One study suggested that ATMs can buffer local increases in lipid 
and suppress local adipocyte lipolysis, decreasing lipid levels in the circulation 
(268). In an effort to test whether LPL silencing in ATMs increased serum FFA 
levels through regulation of lipid release by adipocytes, we found that LPL 
depletion in ATMs had no effect on the expression of hormone-sensitive lipase 
(HSL) and adipose triglyceride lipase (ATGL), involved in lipolysis (Figure 4.3D).  
        LPL silencing in ATMs also resulted in a significant decrease of CD36 and 
diglyceride acyltransferase-2 (DGAT2) expression when measured in SVF cells 
isolated by fluorescence-activated cell sorting (FACS) on the basis of their FITC-
GeRP signal. This was consistent with a decreased FFA uptake and 
esterification by ATMs following LPL silencing (Figure 4.3E). To confirm this 
hypothesis, we measured the percentage of foam cells in AT following fasting-
induced lipolysis (Figure 4.3F). Consistent with the idea that ATMs take up FFA 
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released by adipocytes in fasting condition (268), in obese mice treated with 
PBS, fasting increased the percentage of bodipy+ ATMs (Figure 4.3F). 
Furthermore, flow cytometry analysis showed that the increase in bodipy+ ATMs 
under fasting condition was blocked following LPL silencing in ATMs (Figure 
4.3F). Taken together, these results suggest that silencing LPL unexpectedly 
decreases the capacity of ATMs to take up the excess FFA released by 
adipocytes 
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Figure 4.3 - LPL silencing in ATMs increases plasma FFA 
 
 
Figure 4.3 LPL silencing in ATMs increases plasma FFA  
Serum triglyceride (TG; A) and LDL/VLDL and HDL cholesterol (B) in mice 
treated with scrambled SCR- or LPL-GeRPs; n = 10. (C) Serum FFA levels; n = 
14-15. (D) ATGL and HSL expression in adipocytes isolated from ob/ob mice 
treated with SCR- or LPL-GeRPs; n = 14–15. (E) Gene expression measured by 
RT-PCR in ATMs containing GeRPs sorted by FACS; n = 5. (F) Representative 
dot-plot and percentage of ATMs expressing bodipy in fed and fasted states in 
VAT; n = 10. All graphs are expressed as means + SE. Statistical significance 
was determined by Student’s t-test. ***P < 0.001, *P < 0.05. 
 
 
E 
F 
	  
125	  
Silencing LPL in visceral ATMs exacerbates glucose intolerance in ob/ob 
mice  
        Increased serum FFA levels have been shown to positively regulate glucose 
production by liver (268, 277, 278). The expression of two gluconeogenic 
enzymes, phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-
phosphatase (G6Pase), was significantly increased in livers from ob/ob mice 
treated with LPL-GeRPs compared with SCR-GeRPs (Figure 4.4A). To further 
assess hepatic glucose production, mice were challenged with the gluconeogenic 
precursor pyruvate (Figure 4.4B). Silencing LPL in visceral ATMs exacerbated 
pyruvate intolerance in mice treated with LPL- compared with SCR-GeRPs 
(Figure 4.4B). Given that increased hepatic glucose output often results in 
exacerbated systemic glucose tolerance, we performed glucose tolerance tests 
(GTT) in ob/ob mice treated with LPL-GeRPs or SCR-GeRPs (Figure 4.4C). 
Mice treated with LPL-GeRPs were significantly less glucose tolerant than mice 
treated with SCR-GeRPs (Figure 4.4C). This effect on glucose tolerance 
occurred independently of an effect on insulin tolerance, fasting glucose, or 
insulin levels, or islet morphology (data not shown). Interestingly, treatment of 
lean healthy mice with LPL-GeRPs had no significant effect on glucose tolerance 
or circulating FFA (Figure 4.4D and E).  
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Figure 4.4 - LPL silencing in ATMs exacerbates glucose intolerance in 
ob/ob mice.  
 
Figure 4.4 LPL silencing in ATMs exacerbates glucose intolerance in ob/ob 
mice  
(A): PEPCK and G6Pase expression in liver of ob/ob mice treated with SCR- or 
LPL-GeRPs; n = 10. (B) Pyruvate tolerance test and area under the curve (AUC); 
n = 10. (C) Glucose tolerance tests (GTT) and AUC; n = 14-15, performed on 
mice fasted for 18 h. (D) GTT performed on 8-wk-old C57BL6 lean mice treated 
with SCR- or LPL-GeRPs; n = 5. (E) Serum FFA levels in lean mice treated with 
SCR- or LPL-GeRPs; n = 5. Results are means + SE. Statistical significance was 
determined by t-test or ANOVA and Tukey’s posttest. ***P < 0.001, *P < 0.05. 
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DISCUSSION 
        Most relevant literature describes ATMs as detrimental to whole body 
metabolism through secretion of inflammatory cytokines and other factors that 
may impair adipocyte function (32, 110, 111, 252). However, recent work has 
indicated a beneficial role of ATMs, for example in increasing adipose lipid 
storage (268). We therefore sought to investigate the importance of foam cell 
formation by ATMs. We were able to show that foam cells are present in the 
adipose tissue of mice, and their number increases with obesity (Figure 4.1). 
Interestingly, the lipid expression of LPL, which controls fatty acid uptake from 
the circulation into tissues (273, 274), was also significantly upregulated (Figure 
4.1).  Together, these data indicate that lipid uptake by macrophages in the VAT 
is increased with obesity and could be mediated by LPL. 
        To test our hypothesis of the role of LPL in foam cell formation, we 
specifically knocked down ATM LPL using GeRPs, and saw a marked decrease 
in the number of foam cells (Figure 4.2). This was re-enforced by microscopic 
analysis of VAT and a decrease in lipid-laden macrophages as determined by 
Bodipy+ staining of ATMs from SVF (Figure 4.2). Importantly, This finding is 
consistent with data showing that ATMs mostly accumulate lipids via activation of 
lipid uptake rather than de novo lipogenesis (134). Although lipid uptake by ATMs 
has been suggested to contribute to lipid storage in AT (4, 16), LPL deficiency in 
macrophages throughout the body did not regulate adiposity in mice fed a HFD 
(28). Similarly, we found that although serum FFA was increased, body weight 
	  
128	  
gain, epididymal fad pad weight, and adipocyte number and size were 
unchanged following ATM-specific LPL silencing over this 5 day period (Figure 
4.3). A potential mechanism for this surprising effect may relate to studies 
suggesting that hydrolysis of TG by LPL releases ligands for PPARα/δ 
transcription factors known to drive the expression of lipogenic genes including 
DGAT2 and CD36, which are decreased by ATM LPL silencing (9, 32). However, 
LPL silencing decreased the expression of CD36 and DGAT2, while the 
expression of other PPAR target genes remained unchanged (Figure 4.3). 
Although additional work would be needed to unravel the mechanism whereby 
LPL silencing secondarily decreases CD36 and DGAT2 gene expression, 
previous studies (8, 22) as well as our work suggest that different transcription 
factors, coactivators, or repressors may be involved in the transcriptional 
regulation of lipogenic genes in macrophages deficient in LPL. 
        The impaired ability of ATMs to store lipids also resulted in increased levels 
of hepatic glucose output (Figure 4.4). GTT and PTT performed on obese mice 
that received LPL-GeRPs showed an inability of the liver to regulate systemic 
glucose levels, while lean mice treated with LPL-GeRPs were still able to 
respond within normal parameters compared to the controls (Figure 4.4). This 
confirmed the ability of AT in lean healthy mice to appropriately store lipids and 
the minimal role that ATMs play in this process in lean mice. All together, these 
data suggest ATMs may contribute to lipid storage in the AT of obese mice, thus 
preventing glucose intolerance induced by increased circulating FFA.  
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Chapter V: Activated Kupffer cells inhibit insulin sensitivity in obese mice 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter is derived from an article by the same name published in the 
Federation of American Societies for Experimental Biology Journal. 
Tencerova, M., Aouadi, M., Vangala, P., Nicoloro, S. M., Yawe, J. C., Cohen, J. 
L., Shen, Y., Garcia-Menendez, L., Pedersen, D. J., Gallagher-Dorval, K., 
Perugini, R. A., Gupta, O. T., and Czech, M. P. (2015) Activated Kupffer cells 
inhibit insulin sensitivity in obese mice. FASEB J 29, 2959-2969 
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SUMMARY 
        Obesity promotes insulin resistance associated with liver inflammation, 
elevated glucose production, and T2DM. Although insulin resistance is 
attenuated in genetic mouse models that suppress systemic inflammation, it is 
not clear whether local resident macrophages in liver, Kupffer cells (KCs), directly 
contribute to this syndrome. We addressed this question by selectively silencing 
the expression of the master regulator of inflammation, NF-κB, in KCs in obese 
mice. We used GeRPs that selectively silence gene expression in macrophages 
in vivo. Following intravenous injections, GeRPs containing siRNA against p65 of 
the NF-κB complex caused loss of NF-κB p65 expression in KCs without 
disrupting NF-κB in hepatocytes. Silencing of NF-κB expression in KCs in obese 
mice decreased cytokine secretion and improved insulin sensitivity and glucose 
tolerance. Thus, KCs are key contributors to hepatic insulin resistance in obesity 
and a potential therapeutic target for metabolic disease. 
 
INTRODUCTION 
        Obesity impairs insulin responsiveness in the liver and is associated with 
the development of T2DM with severe comorbid conditions. Although hepatic 
lipid accumulation (77, 279), endoplasmic reticulum stress (280), and 
inflammation (281) have all been suggested as potential contributors to obesity 
induced insulin resistance, the relative causal roles of these factors are still 
unclear. For example, nonalcoholic fatty liver disease is a strong known risk 
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factor for insulin resistance and T2DM (282), but lipid accumulation in liver can 
be experimentally dissociated from insulin resistance under certain conditions 
(283), suggesting that other mechanisms are also involved. Kupffer cells are 
thought to be the major source of hepatic inflammation (284); however, their 
contribution to insulin resistance has not been directly tested because of the lack 
of technology to manipulate gene expression specifically in KCs. Here we used a 
new approach to ask whether these immune cells directly contribute to the 
development of insulin resistance associated with obesity.  
        To investigate the role of KC activation in obesity-induced insulin resistance, 
we developed a method to specifically silence gene expression in these hepatic 
macrophages in vivo. GeRPs loaded with an siRNA against a major regulator of 
inflammatory cytokine expression, NF-κB (191, 215), were delivered to KCs of 
obese mice by intravenous administration. Using this method, we demonstrate 
that silencing NF-k B selectively in KCs decreases liver inflammation and 
improves insulin sensitivity and glucose tolerance in obese mice.  
 
MATERIALS AND METHODS 
Animals and diet: Six-week-old male wild-type C57BL/6J (WT) and 5- and 7- to 
8- week-old male B6.V-Lepob/J (ob/ob) mice were (Jackson Laboratory, Bar 
Harbor, ME, USA) maintained on a 12-hour light/dark cycle. Animals were given 
free access to food and water. C57BL/6J WT mice were fed a high-fat diet (HFD; 
60%calories from lipids; D12492; Research Diets, New Brunswick, NJ, USA) for 
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14 or 24 weeks beginning at 6 weeks of age. All other mice were fed normal 
chow diet. All procedures were performed in accordance with protocols approved 
by the University of Massachusetts Institutional Animal Care and Use Committee. 
 
GeRP administration by intravenous injection in vivo: GeRPs were prepared 
as previously described (Chapter 3). Seven- or 8-week-old genetically obese 
ob/ob mice were treated with 12.5 mg/kg GeRPs loaded with siRNA (247 mg/kg) 
and Endoporter (2.27 mg/kg). Seven-week-old ob/ob mice were used for 
15-day treatment. They received 2 or 6 doses of fluorescently labeled GeRPs by 
intravenous injections over 5 or 15 days, respectively. In a model of diet-induced 
obesity, 6-week-old C57Bl/6J mice were fed a HFD for 14 or 24 weeks. They 
received 6 doses of fluorescently labeled GeRPs for 15 days by intravenous 
injections. siRNA sequences used are as follows: Scrambled (SCR) 5’-
CAGUCGCGUUUGCGACUGGUU-3’; NF-κB/RelA 5’- 
GGAUUGAAGAGAAGCGCAAUU-3’ 
 
Isolation of KCs and hepatocytes: The liver of anesthetized mice was first 
perfused with calcium-free Hanks balanced salt solution, followed by collagenase 
digestion. After digestion, the hepatocytes were released by dissociation from the 
lobes and underwent several steps of filtration with calcium plus Hanks balanced 
salt solution and centrifugation at 50 g for 3 minutes at room temperature. The 
supernatant from the first centrifugation of hepatocytes was loaded on a Percoll 
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gradient (25%and 50%) and centrifuged for 30minutes, at 2300 rpm, at 4°C. The 
interphase ring with KCs was collected and washed 2 times with PBS. The cells 
were cultured overnight. The following day, primary cells were used for 
subsequent analyses. 
 
Western blot: Cell lysates were separated on an 8% SDS-PAGE polyacrylamide 
gel, transferred to a PVDF membrane, and incubated overnight at 4°C with 
primary antibody against p65 (RelA), pSer473 protein kinase B (PKB/AKT), AKT, 
or actin as a loading control (Cell Signaling, Danvers, MA, USA). Anti-rabbit or 
anti-mouse IgG antibody conjugated with horseradish peroxidase was used as a 
secondary antibody. The levels of particular proteins were determined by 
chemiluminescence (Pierce, Rockford, IL, USA). 
 
Isolation of RNA and real-time PCR: As previously described (Chapter 2). 
Primer sequences used are as follows: 36B4 (5’-TCCAGGCTTTGGGCATCA-3’, 
5’-CTTTATCAGCTGCACATCACTCAGA-3’); Clec4f (5’-
GAGGCCGAGCTGAACAGAG-3’, 5’-TGTGAAGCCACCACAAAAAGAG-3’); 
NF-κB/RelA (5’-ACTGCCGGGATGGCTACTAT-3’, 5’-
TCTGGATTCGCTGGCTAATGG-3’); TNF-a (5’-
CCCTCACACTCAGATCATCTTCT-3’, 5’-GCTACGACGTGGGCTACAG-3’); IL-
1b (5’-GCAACTGTTCCTGAACTCAACT-3’, 5’-ATCTTTTGGGGTCCGTCAACT-
3’); IL-6 (5’-TAGTCCTTCCTACCCCAATTTCC-3’, 5’-
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TTGGTCCTTAGCCACTCCTTC-3’); PEPCK (5’-
CTGCATAACGGTCTGGACTTC-3’, 5’-CAGCAACTGCCCGTACTCC-3’); 
G6Pase (5’-GTTGAACCAGTCTCCGACCA-3’, 5’-
CGACTCGCTATCTCCAAGTGA-3’) 
 
Metabolic analyses: 
Glucose and pyruvate tolerance tests (GTTs and PTTs) were performed after 
GeRP treatment (24 hours after last injection) and 6-hour food withdrawal. A 
dose of 1 g/kg glucose or pyruvate was intraperitoneally injected, and blood 
glucose levels were measured by glucometer at defined time points from the tail 
vein. The following day, the mice were killed to harvest tissues for subsequent 
analyses. Insulin-stimulated phosphorylation of AKT in vivo Insulin stimulated 
phosphorylation of AKT was performed after GeRP treatment (24 hours after last 
injection) and 4 hours food withdrawal. A dose of 0.75 U/kg insulin was 
intraperitoneally injected, and then adipose tissue and liver samples were 
harvested from GeRP-treated mice for subsequent analyses 15minutes after 
injection. 
 
Statistical analyses: 
The data were analyzed using GraphPad 5a software (GraphPad Software, La 
Jolla, CA, USA). The statistical significance of differences among groups was 
analyzed using Student t test or ANOVA as appropriate. Data were presented as 
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means + SEM. P < 0.05 was considered statistically significant. 
 
RESULTS 
Specific silencing of NF-κB expression in KCs improves insulin sensitivity 
in genetic obesity mice 
        To test whether we could specifically target KCs for genetic knockdown 
using GeRPs, 8 week old ob/ob mice were injected with either SCR- or NF-κB-
GeRPs for 5 days, after which KCs were isolated (see protocol scheme in Figure 
5.1A). RT-PCR analysis revealed almost a 50% knockdown of NF-κB in animals 
that received NF-κB-GeRPs compared to the SCR group (Figure 5.1B). 
Importantly, there was no knockdown of NF-κB observed in EPI AT, suggesting 
specific targeting of liver KCs (Figure 5.1C). Based on the ability of the 
intravenously delivered GeRPs to specifically silence genes in KCs but not in 
other cells or other organs, and without toxic effects (233), we assessed the 
effect of attenuating inflammation in KCs on insulin resistance in obese mice. 
Seven-week-old ob/ob mice were treated with SCR- or NF-κB-GeRPs for 5 or 15 
days, and GTTs were performed at the end of the treatment (see protocol 
scheme in Figure 5.1A). Although NF-κB silencing in KCs showed no effect on 
glucose tolerance at day 5, we observed a significant improvement at day 16 
(Figure 5.1D). This was accompanied by a decrease in inflammatory gene 
expression (Figure 5.1E). We also observed a decrease in basal fasting 
glycemia in mice after the 15-day treatment compared with 5-day treatment. 
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Although the length of the treatment itself could cause this, it could also be 
explained by the variability in basal glycemia often observed following a short 6-
hour fast.  
        Consistent with the hypothesis that silencing NF-κB in KCs improves insulin 
sensitivity, we observed a significant decrease in the expression of enzymes 
involved in hepatic glucose production, including phosphoenolpyruvate 
carboxykinase and glucose 6-phosphatase expression in mice treated with NF-
κB -GeRPs for compared with SCR-GeRPs for 15 days (Figure 5.1F). 
Consistently, biochemical studies showed an increased insulin-stimulated AKT 
phosphorylation in liver of mice treated with NF-κB -GeRPs at day 16 (Figure 
5.1G). Importantly, silencing NF-κB specifically in KCs had no effect on insulin-
stimulated AKT activation in adipose tissue (Figure 5.1G). 
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Figure 5.1 – Kupffer cell inflammation drives hepatic glucose output in 
ob/ob mice 
	  	   	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	   	  
	  	  
Figure 5.1 Kupffer cell activation drives hepatic glucose output in ob/ob 
mice  
(A) Protocol of 5- and 15-day GeRP treatment. 8-week-old mice were used for 
the 5-day treatment and 7-week-old mice were used for the 15-day treatment. 
mRNA of NF-κB in (B) KCs and (C) EPI AT from mice treated with either SCR-
GeRPs or NF-κB -GeRPs for 15 days (n = 11–13). (D) GTT (1 g/kg) were 
performed on mice treated with SCR- or NF-κB-GeRPs after withholding food for 
6 hours. (E) mRNA levels of inflammatory genes in the liver of ob/ob mice treated 
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15 days with SCR-GeRPs and NF-κB-GeRPs (n= 11-13). (F) mRNA levels of 
gluconeogenic genes in liver from mice treated for 15 days with SCR- or NF-κB-
GeRPs (n = 5). (G) F.C. of AKT phosphorylation by insulin in liver and EPI AT 
measured by densitometry of pSer473-AKT normalized to total AKT. For EPI AT, 
white bars represent saline, black bars represent insulin  (ob/ob, n = 9–10). 
Results are presented as mean of fold change (F.C.) normalized to SCR-
GeRPs–treated mice 6 SEM. *P < 0.05; **P < 0.01. The statistical significance 
was analyzed by t-test or ANOVA followed by Tukey posttest. 
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Specific silencing of NF-κB expression in KCs improves insulin sensitivity 
in diet-induced obesity  
        We next studied the effect of NF-κB-GeRPs in a model of diet-induced 
obesity, which also shows increased liver inflammation (Figure 5.2A). Six-week-
old male C57Bl/6J mice were fed an HFD for 14 or 24 weeks and treated with 
SCR- or NF-κB-GeRPs for 15 days (see protocol scheme in Figure 5.1A) to 
study the effect of NF-κB silencing on liver metabolism at different stages of lipid 
accumulation in the liver. In the 24-week HFD-fed mouse model silencing of NF-
κB in KCs improved fasting hyperglycemia, glucose tolerance, and lowered 
hepatic glucose production from pyruvate as measured by PTT (Figure 5.2B and 
C). Importantly, NF-κB silencing did not affect body weight (Figure 5.2D). 
Consistent with this concept, mice fed a HFD for 14 weeks with NF-κB– depleted 
KCs also exhibited improved glucose tolerance measured by GTT and enhanced 
insulin-stimulated AKT phosphorylation in the liver (Figure 5.2E and F). 
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Figure 5.2 – HFD feeding activates Kupffer cells and induces hepatic 
glucose production 
	   	   	  
	   	   	  
 
Figure 5.2 HFD feeding activates Kupffer cells and incudes hepatic glucose 
production  
(A) Expression of inflammation genes in the liver of mice fed a chow or HFD for 
24 weeks (n=5). (B) GTT (1 g/kg) was performed in mice fed 24 weeks of an 
HFD and treated with SCR- or NF-κB-GeRPs (n = 11–14). (C) PTT (1 g/kg) was 
performed in mice fed a 24-week HFD treated with SCR- or NF-κB-GeRPs after 
withholding food for 6 hours (n = 5). (D) Body weight of 24 week-HFD after a 15-
day treatment with SCR- or NFkB-GeRPs (n=5).  (E) GTT (1 g/kg) was 
performed in mice fed a 14-week HFD and treated with SCR- or NF-κB-GeRPs 
(n = 11–14).  (F) F.C. of AKT phosphorylation by insulin measured by 
densitometry of pSer473-AKT normalized to total AKT (n = 9–10). 
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DISCUSSION 
        In the present study, we demonstrated that silencing NF-κB specifically in 
KCs improved insulin sensitivity independent in diet or genetically induced 
obesity. We used the GeRP technology, developed in our laboratory, to deliver 
siRNA and silence genes specifically in KCs without affecting nonimmune cells in 
the liver and cells in other organs in obese mice. Although various systems have 
been developed to deliver siRNA to the liver, none of these strategies has 
demonstrated the ability to specifically target KCs in liver without affecting 
hepatocytes. Previous studies showing siRNA delivery to KCs in vivo used 
carriers that were also internalized by non-phagocytic cells or phagocytic cells in 
organs other than liver (285-290). In the present study, we accomplished specific 
delivery of GSs to KCs in obese mice by taking advantage of the micrometer-size 
and Dectin 1 receptor-mediated recognition of GS (230). The treatment protocol 
developed for the subsequent experiments requires 15 days, with the 
administration of an injection every 2 days and analysis 24 hrs after the final 
injection. This protocol proved to be more effective in terms of both knockdown 
and improving glucose tolerance compared to a 5-day protocol in ob/ob mice 
(Figure 5.1). 
        In our study, we demonstrated that GeRP-mediated silencing of NF-κB in 
KCs decreased the expression of NF-κB (Figure 5.1). Several studies have 
investigated the role of KCs in insulin resistance in obese mice. These studies 
used systemic delivery of anti-inflammatory drugs, bone marrow transplantation, 
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or transgenic mice deficient in inflammatory genes, which had inhibitory effects 
on insulin resistance (215, 291-293). However, a direct role for inflammation 
could at most only be implied due to the nature of these approaches. Our data 
directly demonstrates that silencing NF-κB in KCs improves insulin sensitivity in 
obese mice (Figure 5.1 and 2). Indeed multiple studies have reported a 
beneficial effect of systemic inhibition of NF-κB or global knockout of its upstream 
activator on liver inflammation and steatosis (191, 291, 294, 295). Silencing NF-
κB for 15 days resulted in a significant improvement of insulin sensitivity, 
measured by GTT, and increased AKT phosphorylation in the liver in ob/ob and 
HFD mice (Figure 5.2). Importantly, GeRPs do not have a toxic effect on the liver 
as determined by liver enzyme measurements (233). Although additional work 
would be needed to unravel the cross talk between KCs and parenchymal cells 
and its impact on liver diseases, the GeRP technology provides a unique tool for 
such studies. 
        Together, these data demonstrate that partial silencing of NF-κB specifically 
in KCs improves insulin sensitivity in diet or genetically induced obesity under our 
experimental conditions. Thus, KC activation and consequent liver inflammation 
play causal roles in the development of insulin resistance in mouse models of 
obesity. 
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CHAPTER VI: Final summary, conclusions and future directions 
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        Macrophage infiltration into adipose tissue and activation of liver Kupffer 
cells are believed to play important roles in the pathology of obesity associated 
T2DM. However, there is lack of direct evidence to support ATM and KC 
involvement in the development of insulin resistance and dysregulated glucose 
metabolism. Our lab has therefore been interested in elucidating the role of 
resident tissue macrophages in the regulation of insulin signaling, the effect on 
energy homeostasis, and how the functions of adipose tissue and liver are 
altered. The work reported in this manuscript was aimed at answering three 
major questions: 
1. What is the source of macrophage accumulation in obese adipose 
tissue?  
2. What is the effect of ATM-specific gene knockdown on the 
development of insulin resistance in obesity?  
3. Does changing the activation state of Kupffer cells affect systemic 
insulin sensitivity in obesity?  
        To address these questions, we employed a number of in vitro and in vivo 
techniques that allowed us to determine that (i) macrophages proliferate locally in 
VAT of genetic and diet-induced models of obesity and MCP-1 plays a direct role 
in promoting proliferation (Chapter2); (ii) GeRP-mediated knockdown of ATM-
derived OPN improves glucose disposal and insulin signaling (Chapter 3); (iii) 
GeRP-mediated knockdown of LPL in ATMs results in impaired lipid buffering, 
increase in hepatic glucose output and decrease in hepatic insulin sensitivity 
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(Chapter 4); (iv) GeRP-mediated depletion of NF-κB in Kupffer cells decreases 
hepatic inflammation and improves insulin signaling in the liver (Chapter 5). 
Below is a schematic representation of these results, followed by discussions of 
my interpretations, potential pitfalls and future directions for the studies 
presented in the chapters above. 
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Figure 6.1 – Macrophages are regulators of whole body metabolism 
 
 
Figure 6.1 Macrophages are regulators of whole body metabolism  
The data in this thesis show that the initial accumulation of macrophages in AT 
might be an adaptive response to AT remodeling and lipid spillover. However, 
with increasing accumulation, a chronic low-grade inflammation develops, 
exerting detrimental effects that lead to the development of insulin resistance. In 
the liver, activated Kupffer cells are responsible for hepatic inflammation, 
promoting hepatic dysfunction and insulin resistance.  
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Local macrophage proliferation in adipose tissue of obese mice 
        In the studies detailed in Chapter 2, we hypothesized that macrophages in 
adipose tissue could proliferate in the context of obesity. We confirmed by FACS 
analysis that the ATM population is indeed increased in both genetic and diet 
induced models of obesity, and this increase was specific to the visceral adipose 
depot (Figure 2.1 and 2.2).  We further demonstrated that this increase was in 
part due to proliferation of resident macrophages by assessing Ki67 staining 
(Figure 2.1 and 2.2). However, the most important finding was the fact that 
macrophages were still able to proliferate without monocyte recruitment from the 
circulation, as demonstrated by depleting the circulating monocyte pool and 
measuring EdU incorporation into macrophage nuclei (Figure 2.3). Based on 
previous literature reports on M1 versus M2 macrophages in obesity, we 
expected the rate of proliferation to be higher in the M1 inflammatory CD11C+ 
cells versus the M2 anti-inflammatory CD11C- macrophages. However, we were 
surprised to observe no significant difference in proliferation rates between the 
two subtypes (data not shown). One could argue that the expansion of one 
subtype population over the other may be regulated by recruitment rather than 
proliferation. Perhaps recruited monocytes also proliferate, which may favor 
inflammatory over anti-inflammatory expansion (248). This would be an 
interesting area for follow up studies, especially to understand whether resident 
proliferating versus recruited proliferating, carry out specific roles within the 
adipose tissue.  
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        By microscopy we determined that proliferating macrophages were primarily 
localized to crown-like structures (Figure 2.3). This could be an important 
indicator of the potential significance of locally proliferating macrophages. 
Adipose tissue is very plastic and therefore requires an efficient mechanism of 
clearing cellular debris as it undergoes rapid remodeling (55). During obesity- 
associated adipose expansion, necrotic adipocytes must be cleared to avoid 
local and potentially systemic toxicity. Therefore, resident macrophages may act 
as sentries that are stimulated to proliferate by dying adipocytes and thereby 
acting as a local response system. The localization of proliferating ATMs around 
individual cells also suggests a spatiotemporal specificity to promoting 
proliferation rather than relying on a system of mass recruitment, thereby 
conserving resources. It also implies that macrophage recruitment is a secondary 
response that is triggered by other secreted factors or the exacerbation of 
adipocyte death. 
        Finally, both MCP-1 and OPN were significantly increased in adipose tissue, 
although only MCP-1 stimulated macrophage proliferation in tissue explants from 
ob/ob mice (Figure 2.4). These results suggested that MCP-1, if not the 
proliferative signal, is at least important for promoting adipose tissue macrophage 
proliferation. One drawback of this approach, however, is the complex nature of 
the adipose tissue, as many different cell types are present. It is possible that 
MCP-1 triggers a paracrine response emanating from non-adipocytes within the 
AT, which subsequently triggers the proliferative response. However our data do 
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not support this hypothesis, as we were not able to detect increased in the 
expression of other important stimulators of proliferation such as M-CSF and IL-4 
(Figure 2.4). Another aspect that requires careful consideration follows from the 
previous discussion about localization of this activity to crown-like structures. The 
effect of explant stimulation on proliferation might be biologically distinct from the 
metabolic response observed in vivo. Since we cannot isolate individual crown-
like structures or necrotic adipocytes, we are unable to specifically recreate the in 
vivo phenomenon. However, such a reductionist approach is likely to also 
introduce confounding factors, since the adipose environment does involve the 
synergistic interaction of different cell types. Therefore, while imperfect, explant 
techniques still serve as the best technique until technological advancements 
allow for a more rigorous approach. 
        In summary, we demonstrated that local proliferation plays a significant role 
in obesity-induced macrophage accumulation in visceral adipose tissue 
independent of monocyte recruitment. Although some of the techniques 
employed are not transferrable to human studies, determining whether this 
observation is conserved in humans would help further our understanding of 
obesity associated inflammation. Additionally, this could impact future research 
involving the blockade of macrophage infiltration, emphasizing a dual approach 
that also takes into account proliferation.  
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ATM-specific gene knockdown affects whole body metabolism 
        In Chapters 3 and 4, we utilized a novel approach involving GeRPs, a tool 
developed by our laboratory, to specifically downregulate ATM gene expression. 
We first determined the biodistribution of GeRPs injected i.p. into obese mice, 
since we had previously observed that lean animals exhibited a systemic 
distribution (228, 230). Surprisingly, we found that in obese mice, GeRPs were 
localized to the epididymal adipose tissue (Figure 3.1). Upon sorting cells from 
this depot, we confirmed that GeRPs were specifically taken up by macrophages 
(Figure 3.2). Considering the obesity-induced accumulation of macrophages in 
VAT compared to other tissue types and fat depots, this specificity suggests that 
GeRPs localize to areas of inflammation or macrophage concentration. This 
property makes GeRPs uniquely suited for the targeting of macrophages, and 
particularly ATMs in the case of obesity-induced inflammation of adipose tissue. 
It is still unclear whether GeRPs are taken up by resident macrophages, or taken 
up first by circulating monocytes that subsequently infiltrate the adipose tissue.  
However, the latter is the most likely scenario given the route of administration. 
One way to answer this question would involve using the clodronate liposomes 
as employed in chapter 2, then injecting mice with GeRPs to determine whether 
they are still phagocytosed by ATMs. 
        OPN was selected as one of the target genes for GeRP-mediated silencing 
because its expression in VAT positively correlates with obesity in humans and 
rodents (209-211). We also confirmed this result by analyzing GeneChip® data in 
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our database of human and mouse adipose tissue samples (data not shown), 
and by measuring Opn gene expression in ob/ob mice (Figure 3.3). OPN-GeRP 
administration resulted in a 50% knockdown of OPN expression in adipose tissue 
and about a 90% knockdown in sorted macrophages (Figure 3.4). Importantly, a 
reduction in OPN protein was also observed. These data, together with the lack 
of significant changes in the expression of other macrophage genes, or changes 
in liver OPN expression, gave us confidence in the specificity of our knockdown 
(Figure 3.4). Knockdown resulted in a significant improvement in both glucose 
and insulin tolerance compared to mice that received SCR-GeRPs, without 
changes in weight gain or insulin secretion (Figure 3.5). Because OPN is a 
secreted protein that circulates at high concentrations, we determined whether 
knockdown in ATMs had altered circulating levels. This would perhaps indicate 
that serum OPN levels were regulating hepatic glucose output. However, there 
was no change in serum OPN concentrations after knockdown (Figure 3.5). This 
implies that OPN acts locally on adipose tissue to promote insulin resistance.  
        Indeed comparing AKT phosphorylation on serine 473 in adipose, muscle 
and liver tissues of mice that were treated with OPN-GeRPs revealed an 
increase in insulin signaling only in the adipose tissue (Figure 3.6). These data 
prompted further analysis of the adipose tissue, particularly looking at the 
expression of key adipocyte genes involved in adipogenesis and lipogenesis i.e., 
PPARγ, FASN, GLUT4, SCD1, Adiponectin, CPT1b and SREBP1c. I found that 
although there was a general trend toward an increase, only PPARγ and FASN 
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were significantly upregulated in adipocytes following OPN knockdown in ATMs 
(Figure 3.6). This suggested that depleting OPN was perhaps improving 
adipocyte dysfunction by promoting adipogenesis and lipogenesis. I tested this 
hypothesis by comparing fat pads taken from mice treated with SCR-GeRPs 
versus OPN-GeRPs, measuring mass, adipocyte size and adipocyte number. 
However, there were no differences observed in any of these parameters (data 
not shown). Functional assays using radiolabeled glucose to determine rates of 
glucose uptake or incorporation into triglycerides might provide more information 
moving forward.   
        One interesting observation after OPN knockdown was the lack of a 
significant effect on inflammatory gene expression in adipose tissue. Some pro-
inflammatory genes trended toward a decrease while some anti-inflammatory 
genes trended toward an increase (Figure 3.4). Perhaps a longer treatment 
protocol would result in more pronounced and significant differences. 
Additionally, beta glucans themselves have shown glucose lowering effects in 
T2DM when administered orally, though the underlying mechanisms are not well 
understood (296). However, most studies have focused on oral administration of 
beta glucans. Liu et al. found oat beta glucan to have anti-inflammatory effects in 
ulcerative colitis by suppression of pro-inflammatory cytokine expression (297). 
Thus in our model the glucan shells might exert similar effects, although the 
observed improvement in glucose metabolism likely stems from OPN 
knockdown. As adipose inflammation is not significantly changed, OPN itself 
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must be interacting with adipocytes either indirectly or via a receptor. Indeed, 
OPN reportedly binds surface integrins and the CD44 receptor, causing 
downstream effects including activation of inflammatory pathways, decreased 
insulin stimulated glucose uptake and reduced adipocyte differentiation (298). 
Identifying an OPN receptor in our model would create a better understanding of 
how it affects adipocyte biology and the beneficial effects observed depletion of 
OPN.     
        LPL was the second ATM gene that was targeted using the GeRP 
technology, because of its role in foam cell formation (275, 276). Thus we 
assessed the effect of blocking foam cell formation in adipose tissue on systemic 
metabolic parameters. First, we confirmed the presence of foam cells in VAT of 
obese ob/ob mice by FACS analysis, immunofluorescence microscopy and 
transmission electron microscopy (TEM) (Figure 4.1). In addition, measurement 
of a number of lipid processing genes revealed that LPL was significantly 
upregulated in ATMs of obese mice compared to wild type controls (Figure 4.1). 
Using LPL-GeRPs via i.p. injection, foam cells were depleted. Using this method, 
ATMs were specifically targeted, resulting in reduced foam cell formation as 
determined by TEM and lipid staining (Figure 4.2). This ATM-specific knockdown 
also resulted in increased circulating FFA without affecting TAG or cholesterol 
levels. CD36 and DGAT2 expression were also decreased, implying a decrease 
in FFA uptake and TAG formation, similar to what was observed in a 
macrophage specific LPL KO model (Figure 4.3) (276). Foam cell formation was 
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also observed in fasted mice, likely because fasting results in lipid mobilization 
via TAG lipolysis and secretion of FFA. The decrease in foam cell formation in 
fasted LPL-GeRP treated animals confirms the role of ATMs in lipid buffering in 
adipose tissue (Figure 4.3).  
        The effect of LPL knockdown in ATMs on systemic glucose levels and 
hepatic gluconeogenic enzymes highlights the significance of adipose tissue in 
regulating glucose metabolism. Obese mice that were treated with LPL-GeRPs 
showed exacerbated glucose and pyruvate tolerance, as well as increased 
expression of the gluconeogenic enzymes PEPCK and G6Pase (Figure 4.4). 
Indeed a recent study by Perry et al. has linked increased hepatic glucose output 
to an increase in circulating FFA from adipose tissue, resulting from adipose 
tissue inflammation. Increased FFA flux to the liver results in increased hepatic 
acetyl CoA, which activates pyruvate carboxylase activity and thus drives 
glucose production (87).  
        In summary, the work detailed in Chapters 3 and 4 describes a method of 
reprogramming macrophages in the adipose tissue of obese mice. These 
methods reprogrammed ATMs via gene silencing to either improve metabolic 
homeostasis or exacerbate its dysregulation. Thus we have shown the 
advantage of GeRPs in specifically targeting ATMs, and more importantly the 
significance of ATMs in regulating whole body metabolism.   
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Kupffer cell activation promotes insulin resistance  
        In Chapter 5 we sought to apply the GeRP technology in a different manner 
by targeting hepatic Kupffer cells. Instead of the i.p. route used for ATM 
targeting, we used intravenous injections to deliver GeRPs to the liver. Indeed 
biodistribution studies of radiolabeled GeRPs confirmed that most GeRPs 
administered in this fashion were specifically delivered to the livers of ob/ob mice 
(233). We selected NF-κB as our target gene due to its role in macrophage 
activation as observed by cytokine production, and insulin resistance as 
determined by metabolic and molecular analysis (191, 215). We observed that 
NF-κB knockdown specifically in KCs, did not affect gene expression in VAT, and 
was accompanied by reduced expression of inflammatory cytokines such as IL-
1β and TNFα (Figure 5.1). The improved hepatic insulin signaling and decrease 
in gluconeogenic enzyme expression following NF-κB knockdown suggest that 
Kupffer cell activation is responsible for stimulating hepatic glucose output in 
obese mice (Figure 5.1). Further studies will measure the protein levels and 
activity of these enzymes as well.  
        This work was replicated using a high fat diet model of obesity. Mice were 
placed on a 60% HFD for 24 weeks, and RT-PCR analysis of inflammatory 
genes revealed an increase in hepatic inflammatory gene expression, similar as 
others have shown (Figure 5.2). Therefore, we treated mice with NF-κB-GeRPs 
and assessed changes in metabolic parameters and hepatic insulin signaling. As 
with the ob/ob mice, a significant improvement in glucose tolerance as well as 
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reduced pyruvate conversion to glucose was observed. The improvement in 
glucose tolerance was observed as early as 14 weeks on HFD, a time point at 
which increased AKT phosphorylation, which is indicative of improved insulin 
signaling, was also observed (Figure 5.2). Similar to OPN knockdown in ATMs, 
NF-κB knockdown in KCs improved insulin signaling without affecting body 
weight (Figure 5.2). This is important because weight loss is an important factor 
in improving insulin sensitivity in humans. However, many are incapable of 
adopting long lasting lifestyle changes that prevent regaining weight. This 
treatment modality would be a promising avenue to explore in terms of 
developing therapies for obese human patients. In summary, GeRP technology 
was used to reprogram or “deactivate” liver Kupffer cells, thus reducing hepatic 
inflammation and improving hepatic insulin signaling.  
        Overall, this thesis illustrates the complex role of macrophages in metabolic 
tissues in obesity and metabolic disease. Using gene targeting metjods we have 
discovered that tissue specific macrophages play both pro and anti-inflammatory 
roles and can improve or worsen metabolic health depending on the genes 
expressed within. Further studies could be geared toward applying GeRP 
technology to further elucidate the role of macrophages in T2DM, as well as 
other clinical indications, without creating mutant strains. Naturally, such 
advancements would also facilitate the development of more effective therapies. 
It is also important to note that although our work shows that macrophages can 
be reprogrammed to affect changes in metabolism, there might be ways to affect 
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changes in the immune system, particularly the innate immune response. 
Macrophage research continues to be an active area of interest, and with the 
addition of GeRP technology to the tool kit we come one step further to better 
understanding the sum of their functions.   
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